<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-title-group><journal-title>EBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27810310</article-id><article-id pub-id-type="pmc">5264483</article-id><article-id pub-id-type="publisher-id">S2352-3964(16)30497-2</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2016.10.036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial<sup><xref ref-type="fn" rid="d32e3672">☆</xref></sup><sup><xref ref-type="fn" rid="d32e3677">☆☆</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stenman</surname><given-names>Lotta K.</given-names></name><email>lotta.stenman@dupont.com</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><name><surname>Lehtinen</surname><given-names>Markus J.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Meland</surname><given-names>Nils</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Christensen</surname><given-names>Jeffrey E.</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Yeung</surname><given-names>Nicolas</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Saarinen</surname><given-names>Markku T.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Courtney</surname><given-names>Michael</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Burcelin</surname><given-names>Rémy</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Lähdeaho</surname><given-names>Marja-Leena</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Linros</surname><given-names>Jüri</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Apter</surname><given-names>Dan</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Scheinin</surname><given-names>Mika</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Kloster Smerud</surname><given-names>Hilde</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Rissanen</surname><given-names>Aila</given-names></name><xref rid="af0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Lahtinen</surname><given-names>Sampo</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Global Health and Nutrition Science, DuPont Nutrition &amp; Health, FI-02460 Kantvik, Finland</aff><aff id="af0010"><label>b</label>Smerud Medical Research, N-0212 Oslo, Norway</aff><aff id="af0015"><label>c</label>Vaiomer S.A.S, FR-31670 Labège, France</aff><aff id="af0020"><label>d</label>FinnMedi, FI-33520 Tampere, Finland</aff><aff id="af0025"><label>e</label>Kerava Health Centre, FI-04200 Kerava, Finland</aff><aff id="af0030"><label>f</label>VL-Medi, FI-00101 Helsinki, Finland</aff><aff id="af0035"><label>g</label>Clinical Research Services Turku, FI-20520 Turku, Finland</aff><aff id="af0040"><label>h</label>Obesity Research Unit, University of Helsinki, FI-00290 Helsinki, Finland</aff><author-notes><corresp id="cr0005"><label>⁎</label>Corresponding author at: DuPont Nutrition &amp; Health, Sokeritehtaantie 20, FI-02460 Kantvik, Finland.DuPont Nutrition &amp; HealthSokeritehtaantie 20KantvikFI-02460Finland <email>lotta.stenman@dupont.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>26</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>26</day><month>10</month><year>2016</year></pub-date><volume>13</volume><fpage>190</fpage><lpage>200</lpage><history><date date-type="received"><day>19</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>17</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0005"><sec><title><offsets xml_i="5607" xml_f="5617" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5628" xml_f="5799" txt_i="22" txt_f="193">The gut microbiota is interlinked with obesity, but direct evidence of effects of its modulation on body fat mass is still scarce. We investigated the possible effects of </offsets><italic><offsets xml_i="5807" xml_f="5831" txt_i="193" txt_f="217">Bifidobacterium animalis</offsets></italic><italic><offsets xml_i="5848" xml_f="5859" txt_i="217" txt_f="228">ssp. lactis</offsets></italic><offsets xml_i="5868" xml_f="5989" txt_i="228" txt_f="349"> 420 (B420) and the dietary fiber Litesse® Ultra polydextrose (LU) on body fat mass and other obesity-related parameters.</offsets></p></sec><sec><title><offsets xml_i="6011" xml_f="6018" txt_i="351" txt_f="358">Methods</offsets></title><p><offsets xml_i="6029" xml_f="6280" txt_i="359" txt_f="610">225 healthy volunteers (healthy, BMI 28–34.9) were randomized into four groups (1:1:1:1), using a computer-generated sequence, for 6 months of double-blind, parallel treatment: 1) Placebo, microcrystalline cellulose, 12 g/d; 2) LU, 12 g/d; 3) B420, 10</offsets><sup><offsets xml_i="6285" xml_f="6287" txt_i="610" txt_f="612">10</offsets></sup><offsets xml_i="6293" xml_f="6362" txt_i="612" txt_f="681"> CFU/d in microcrystalline cellulose, 12 g/d; 4) LU + B420, 12 g + 10</offsets><sup><offsets xml_i="6367" xml_f="6369" txt_i="681" txt_f="683">10</offsets></sup><offsets xml_i="6375" xml_f="6679" txt_i="683" txt_f="987"> CFU/d. Body composition was monitored with dual-energy X-ray absorptiometry, and the primary outcome was relative change in body fat mass, comparing treatment groups to Placebo. Other outcomes included anthropometric measurements, food intake and blood and fecal biomarkers. The study was registered in </offsets><ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov" id="ir0005"><offsets xml_i="6760" xml_f="6778" txt_i="987" txt_f="1005">Clinicaltrials.gov</offsets></ext-link><offsets xml_i="6789" xml_f="6791" txt_i="1005" txt_f="1007"> (</offsets><ext-link ext-link-type="uri" xlink:href="ctgov:NCT01978691" id="ir0010"><offsets xml_i="6864" xml_f="6875" txt_i="1007" txt_f="1018">NCT01978691</offsets></ext-link><offsets xml_i="6886" xml_f="6888" txt_i="1018" txt_f="1020">).</offsets></p></sec><sec><title><offsets xml_i="6910" xml_f="6918" txt_i="1022" txt_f="1030">Findings</offsets></title><p><offsets xml_i="6929" xml_f="7006" txt_i="1031" txt_f="1108">There were marked differences in the results of the Intention-To-Treat (ITT; </offsets><italic><offsets xml_i="7014" xml_f="7015" txt_i="1108" txt_f="1109">n</offsets></italic><offsets xml_i="7024" xml_f="7054" txt_i="1109" txt_f="1139"> = 209) and Per Protocol (PP; </offsets><italic><offsets xml_i="7062" xml_f="7063" txt_i="1139" txt_f="1140">n</offsets></italic><offsets xml_i="7072" xml_f="7642" txt_i="1140" txt_f="1707"> = 134) study populations. The PP analysis included only those participants who completed the intervention with &gt; 80% product compliance and no antibiotic use. In addition, three participants were excluded from DXA analyses for PP due to a long delay between the end of intervention and the last DXA measurement. There were no significant differences between groups in body fat mass in the ITT population. However, LU + B420 and B420 seemed to improve weight management in the PP population. For relative change in body fat mass, LU + B420 showed a − 4.5% (− 1.4 kg, </offsets><italic><offsets xml_i="7650" xml_f="7651" txt_i="1707" txt_f="1708">P</offsets></italic><offsets xml_i="7660" xml_f="7669" txt_i="1708" txt_f="1717"> = 0.02, </offsets><italic><offsets xml_i="7677" xml_f="7678" txt_i="1717" txt_f="1718">N</offsets></italic><offsets xml_i="7687" xml_f="7747" txt_i="1718" txt_f="1778"> = 37) difference to the Placebo group, whereas LU (+ 0.3%, </offsets><italic><offsets xml_i="7755" xml_f="7756" txt_i="1778" txt_f="1779">P</offsets></italic><offsets xml_i="7765" xml_f="7774" txt_i="1779" txt_f="1788"> = 1.00, </offsets><italic><offsets xml_i="7782" xml_f="7783" txt_i="1788" txt_f="1789">N</offsets></italic><offsets xml_i="7792" xml_f="7817" txt_i="1789" txt_f="1814"> = 35) and B420 (− 3.0%, </offsets><italic><offsets xml_i="7825" xml_f="7826" txt_i="1814" txt_f="1815">P</offsets></italic><offsets xml_i="7835" xml_f="7844" txt_i="1815" txt_f="1824"> = 0.28, </offsets><italic><offsets xml_i="7852" xml_f="7853" txt_i="1824" txt_f="1825">N</offsets></italic><offsets xml_i="7862" xml_f="7904" txt_i="1825" txt_f="1867"> = 24) alone had no effect (overall ANOVA </offsets><italic><offsets xml_i="7912" xml_f="7913" txt_i="1867" txt_f="1868">P</offsets></italic><offsets xml_i="7922" xml_f="7940" txt_i="1868" txt_f="1886"> = 0.095, Placebo </offsets><italic><offsets xml_i="7948" xml_f="7949" txt_i="1886" txt_f="1887">N</offsets></italic><offsets xml_i="7958" xml_f="8030" txt_i="1887" txt_f="1959"> = 35). A post-hoc factorial analysis was significant for B420 (− 4.0%, </offsets><italic><offsets xml_i="8038" xml_f="8039" txt_i="1959" txt_f="1960">P</offsets></italic><offsets xml_i="8048" xml_f="8513" txt_i="1960" txt_f="2425"> = 0.002 vs. Placebo). Changes in fat mass were most pronounced in the abdominal region, and were reflected by similar changes in waist circumference. B420 and LU + B420 also significantly reduced energy intake compared to Placebo. Changes in blood zonulin levels and hsCRP were associated with corresponding changes in trunk fat mass in the LU + B420 group and in the overall population. There were no differences between groups in the incidence of adverse events.</offsets></p></sec><sec><title><offsets xml_i="8535" xml_f="8545" txt_i="2427" txt_f="2437">Discussion</offsets></title><p><offsets xml_i="8556" xml_f="8793" txt_i="2438" txt_f="2675">This clinical trial demonstrates that a probiotic product with or without dietary fiber controls body fat mass. B420 and LU + B420 also reduced waist circumference and food intake, whereas LU alone had no effect on the measured outcomes.</offsets></p></sec></abstract><abstract abstract-type="author-highlights" id="ab0010"><title><offsets xml_i="8877" xml_f="8887" txt_i="2688" txt_f="2698">Highlights</offsets></title><p><list list-type="simple"><list-item id="u0005"><label><offsets xml_i="8952" xml_f="8953" txt_i="2699" txt_f="2700">•</offsets></label><p><offsets xml_i="8964" xml_f="9081" txt_i="2700" txt_f="2817">The probiotic B420 and synbiotic LU + B420 seem to control body fat mass in humans, especially in the abdominal area.</offsets></p></list-item><list-item id="u0010"><label><offsets xml_i="9126" xml_f="9127" txt_i="2818" txt_f="2819">•</offsets></label><p><offsets xml_i="9138" xml_f="9247" txt_i="2819" txt_f="2928">B420 and LU + B420 reduce waist circumference and energy intake, but only LU + B420 increases lean body mass.</offsets></p></list-item><list-item id="u0015"><label><offsets xml_i="9292" xml_f="9293" txt_i="2929" txt_f="2930">•</offsets></label><p><offsets xml_i="9304" xml_f="9426" txt_i="2930" txt_f="3052">Reduced body fat is associated with zonulin, a marker of epithelial permeability, supporting earlier preclinical findings.</offsets></p></list-item></list></p><p><offsets xml_i="9456" xml_f="10109" txt_i="3054" txt_f="3707">Concise results on probiotics for weight management are lacking. Stenman et al. show in a gold standard clinical study that the probiotic B420 with or without a fiber controls body fat, waist circumference and energy intake when taken in a dietary intervention of six months. Study participants maintained habitual diet and physical activity. Stenman et al. link the benefit to changes in serum zonulin, a potential gut permeability marker. The authors have previously shown in animal studies that these gut microbiota targeting products improve metabolic health in mice by strengthening gut barrier function. These effects are now translated to humans.</offsets></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Clinical trial</kwd><kwd>Fiber</kwd><kwd>Obesity</kwd><kwd>Prebiotic</kwd><kwd>Probiotic</kwd><kwd>Synbiotic</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label><offsets xml_i="10353" xml_f="10354" txt_i="3715" txt_f="3716">1</offsets></label><title><offsets xml_i="10369" xml_f="10381" txt_i="3716" txt_f="3728">Introduction</offsets></title><p><offsets xml_i="10392" xml_f="10561" txt_i="3729" txt_f="3898">The gut microbiota is associated with metabolic disorders such as obesity and type 2 diabetes. Since the discovery of a link between gut microbiota and obesity in 2006 (</offsets><xref rid="bb0230" ref-type="bibr"><offsets xml_i="10596" xml_f="10618" txt_i="3898" txt_f="3920">Turnbaugh et al., 2006</offsets></xref><offsets xml_i="10625" xml_f="10627" txt_i="3920" txt_f="3922">, </offsets><xref rid="bb0105" ref-type="bibr"><offsets xml_i="10662" xml_f="10678" txt_i="3922" txt_f="3938">Ley et al., 2006</offsets></xref><offsets xml_i="10685" xml_f="10808" txt_i="3938" txt_f="4061">), increasing evidence has been presented to suggest a causal relationship between gut microbiota and metabolic disorders (</offsets><xref rid="bb0205" ref-type="bibr"><offsets xml_i="10843" xml_f="10864" txt_i="4061" txt_f="4082">Stenman et al., 2015a</offsets></xref><offsets xml_i="10871" xml_f="10873" txt_i="4082" txt_f="4084">).</offsets></p><p><offsets xml_i="10880" xml_f="11070" txt_i="4085" txt_f="4275">One of the mechanisms postulated to explain this relationship is the metabolic endotoxemia hypothesis, which links gut microbes to low-grade inflammation and further to metabolic disorders (</offsets><xref rid="bb0020" ref-type="bibr"><offsets xml_i="11105" xml_f="11126" txt_i="4275" txt_f="4296">Burcelin et al., 2009</offsets></xref><offsets xml_i="11133" xml_f="11135" txt_i="4296" txt_f="4298">, </offsets><xref rid="bb0025" ref-type="bibr"><offsets xml_i="11170" xml_f="11187" txt_i="4298" txt_f="4315">Cani et al., 2007</offsets></xref><offsets xml_i="11194" xml_f="11222" txt_i="4315" txt_f="4343">). In experimental animals (</offsets><xref rid="bb0195" ref-type="bibr"><offsets xml_i="11257" xml_f="11277" txt_i="4343" txt_f="4363">Stenman et al., 2012</offsets></xref><offsets xml_i="11284" xml_f="11286" txt_i="4363" txt_f="4365">, </offsets><xref rid="bb0015" ref-type="bibr"><offsets xml_i="11321" xml_f="11338" txt_i="4365" txt_f="4382">Brun et al., 2007</offsets></xref><offsets xml_i="11345" xml_f="11367" txt_i="4382" txt_f="4404">) and also in humans (</offsets><xref rid="bb0215" ref-type="bibr"><offsets xml_i="11402" xml_f="11423" txt_i="4404" txt_f="4425">Teixeira et al., 2012</offsets></xref><offsets xml_i="11430" xml_f="11432" txt_i="4425" txt_f="4427">, </offsets><xref rid="bb0100" ref-type="bibr"><offsets xml_i="11467" xml_f="11485" txt_i="4427" txt_f="4445">Leber et al., 2012</offsets></xref><offsets xml_i="11492" xml_f="11635" txt_i="4445" txt_f="4588">), obesity and metabolic disorders have been associated with an impaired gut barrier, which may lead to increased translocation of endotoxins (</offsets><xref rid="bb0080" ref-type="bibr"><offsets xml_i="11670" xml_f="11689" txt_i="4588" txt_f="4607">Kallio et al., 2015</offsets></xref><offsets xml_i="11696" xml_f="11698" txt_i="4607" txt_f="4609">, </offsets><xref rid="bb0200" ref-type="bibr"><offsets xml_i="11733" xml_f="11753" txt_i="4609" txt_f="4629">Stenman et al., 2014</offsets></xref><offsets xml_i="11760" xml_f="11809" txt_i="4629" txt_f="4678">), especially in connection with a Western diet (</offsets><xref rid="bb0155" ref-type="bibr"><offsets xml_i="11844" xml_f="11865" txt_i="4678" txt_f="4699">Pendyala et al., 2012</offsets></xref><offsets xml_i="11872" xml_f="11995" txt_i="4699" txt_f="4822">). These highly inflammatory components can ultimately lead to tissue inflammation and, consequently, metabolic disorders (</offsets><xref rid="bb0020" ref-type="bibr"><offsets xml_i="12030" xml_f="12051" txt_i="4822" txt_f="4843">Burcelin et al., 2009</offsets></xref><offsets xml_i="12058" xml_f="12060" txt_i="4843" txt_f="4845">).</offsets></p><p><offsets xml_i="12067" xml_f="12374" txt_i="4846" txt_f="5153">Dietary recommendations have been put forward to try to prevent metabolic disorders. In the Finnish Diabetes Prevention Study, carried out in a large cohort of middle-aged participants with impaired glucose tolerance, a simple lifestyle intervention reduced the risk of diabetes by 58% compared to control (</offsets><xref rid="bb0225" ref-type="bibr"><offsets xml_i="12409" xml_f="12432" txt_i="5153" txt_f="5176">Tuomilehto et al., 2001</offsets></xref><offsets xml_i="12439" xml_f="12821" txt_i="5176" txt_f="5558">). Of those subjects with excellent adherence to the intervention program, meeting four of the five intervention goals, none developed type 2 diabetes. Still, in the general population, the prevalence of metabolic disorders is rapidly increasing, and supportive prevention options—such as those targeting the gut microbiota—need to be developed to support current standards of care.</offsets></p><p><offsets xml_i="12828" xml_f="12905" txt_i="5559" txt_f="5636">Probiotics are live micro-organisms that confer health benefits to the host (</offsets><xref rid="bb0055" ref-type="bibr"><offsets xml_i="12940" xml_f="12957" txt_i="5636" txt_f="5653">Hill et al., 2014</offsets></xref><offsets xml_i="12964" xml_f="13061" txt_i="5653" txt_f="5750">), whereas prebiotics are fibers that selectively improve the growth of beneficial gut microbes (</offsets><xref rid="bb0045" ref-type="bibr"><offsets xml_i="13096" xml_f="13123" txt_i="5750" txt_f="5777">Gibson and Roberfroid, 1995</offsets></xref><offsets xml_i="13130" xml_f="13188" txt_i="5777" txt_f="5835">). In experimental animals, we have previously shown that </offsets><italic><offsets xml_i="13196" xml_f="13220" txt_i="5835" txt_f="5859">Bifidobacterium animalis</offsets></italic><offsets xml_i="13229" xml_f="13235" txt_i="5859" txt_f="5865"> ssp. </offsets><italic><offsets xml_i="13243" xml_f="13249" txt_i="5865" txt_f="5871">lactis</offsets></italic><offsets xml_i="13258" xml_f="13379" txt_i="5871" txt_f="5992"> 420 (B420) prevented weight gain, improved insulin sensitivity, as well as reduced endotoxemia and tissue inflammation (</offsets><xref rid="bb0005" ref-type="bibr"><offsets xml_i="13414" xml_f="13431" txt_i="5992" txt_f="6009">Amar et al., 2011</offsets></xref><offsets xml_i="13438" xml_f="13440" txt_i="6009" txt_f="6011">, </offsets><xref rid="bb0200" ref-type="bibr"><offsets xml_i="13475" xml_f="13495" txt_i="6011" txt_f="6031">Stenman et al., 2014</offsets></xref><offsets xml_i="13502" xml_f="13504" txt_i="6031" txt_f="6033">, </offsets><xref rid="bb0210" ref-type="bibr"><offsets xml_i="13539" xml_f="13560" txt_i="6033" txt_f="6054">Stenman et al., 2015b</offsets></xref><offsets xml_i="13567" xml_f="13569" txt_i="6054" txt_f="6056">, </offsets><xref rid="bb0040" ref-type="bibr"><offsets xml_i="13604" xml_f="13624" txt_i="6056" txt_f="6076">Garidou et al., 2015</offsets></xref><offsets xml_i="13631" xml_f="13733" txt_i="6076" txt_f="6178">). The probiotic B420 has been given to humans in earlier clinical trials, albeit at quite low doses (</offsets><xref rid="bb0085" ref-type="bibr"><offsets xml_i="13768" xml_f="13786" txt_i="6178" txt_f="6196">Klein et al., 2008</offsets></xref><offsets xml_i="13793" xml_f="13795" txt_i="6196" txt_f="6198">, </offsets><xref rid="bb0175" ref-type="bibr"><offsets xml_i="13830" xml_f="13851" txt_i="6198" txt_f="6219">Roessler et al., 2008</offsets></xref><offsets xml_i="13858" xml_f="13860" txt_i="6219" txt_f="6221">, </offsets><xref rid="bb0090" ref-type="bibr"><offsets xml_i="13895" xml_f="13911" txt_i="6221" txt_f="6237">Kok et al., 1996</offsets></xref><offsets xml_i="13918" xml_f="13939" txt_i="6237" txt_f="6258">), but its potential </offsets><italic><offsets xml_i="13947" xml_f="13951" txt_i="6258" txt_f="6262">anti</offsets></italic><offsets xml_i="13960" xml_f="14197" txt_i="6262" txt_f="6499">-obesity effects have remained unexplored. The prebiotic employed in the current study, Litesse® Ultra polydextrose (LU), is a randomly cross-linked polymer of glucose, which remains undigested by the host and may increase the number of </offsets><italic><offsets xml_i="14205" xml_f="14219" txt_i="6499" txt_f="6513">Bifidobacteria</offsets></italic><offsets xml_i="14228" xml_f="14269" txt_i="6513" txt_f="6554"> in a colonic continuous culture system (</offsets><xref rid="bb0165" ref-type="bibr"><offsets xml_i="14304" xml_f="14324" txt_i="6554" txt_f="6574">Probert et al., 2004</offsets></xref><offsets xml_i="14331" xml_f="14392" txt_i="6574" txt_f="6635">). Its administration has been reported to induce satiation (</offsets><xref rid="bb0060" ref-type="bibr"><offsets xml_i="14427" xml_f="14446" txt_i="6635" txt_f="6654">Ibarra et al., 2015</offsets></xref><offsets xml_i="14453" xml_f="14514" txt_i="6654" txt_f="6715">) and to ameliorate the glycemic response to a glucose load (</offsets><xref rid="bb0065" ref-type="bibr"><offsets xml_i="14549" xml_f="14565" txt_i="6715" txt_f="6731">Jie et al., 2000</offsets></xref><offsets xml_i="14572" xml_f="14649" txt_i="6731" txt_f="6808">), indicating potential benefits for weight maintenance and metabolic health.</offsets></p><p><offsets xml_i="14656" xml_f="14817" txt_i="6809" txt_f="6970">To date, there is no conclusive evidence for the ability of probiotics to control body fat mass in humans. Despite a fair amount of promising clinical findings (</offsets><xref rid="bb0185" ref-type="bibr"><offsets xml_i="14852" xml_f="14872" txt_i="6970" txt_f="6990">Sanchez et al., 2014</offsets></xref><offsets xml_i="14879" xml_f="14881" txt_i="6990" txt_f="6992">, </offsets><xref rid="bb0070" ref-type="bibr"><offsets xml_i="14916" xml_f="14936" txt_i="6992" txt_f="7012">Kadooka et al., 2010</offsets></xref><offsets xml_i="14943" xml_f="14945" txt_i="7012" txt_f="7014">, </offsets><xref rid="bb0075" ref-type="bibr"><offsets xml_i="14980" xml_f="15000" txt_i="7014" txt_f="7034">Kadooka et al., 2013</offsets></xref><offsets xml_i="15007" xml_f="15009" txt_i="7034" txt_f="7036">, </offsets><xref rid="bb0140" ref-type="bibr"><offsets xml_i="15044" xml_f="15066" txt_i="7036" txt_f="7058">Osterberg et al., 2015</offsets></xref><offsets xml_i="15073" xml_f="15345" txt_i="7058" txt_f="7330">), randomized controlled trials demonstrating beneficial probiotic effects in the primary statistical analysis of a well-powered study conducted according to Good Clinical Practice (GCP) are lacking. Only few studies on prebiotics have shown effects on weight management (</offsets><xref rid="bb0150" ref-type="bibr"><offsets xml_i="15380" xml_f="15404" txt_i="7330" txt_f="7354">Parnell and Reimer, 2009</offsets></xref><offsets xml_i="15411" xml_f="15413" txt_i="7354" txt_f="7356">, </offsets><xref rid="bb0110" ref-type="bibr"><offsets xml_i="15448" xml_f="15463" txt_i="7356" txt_f="7371">Li et al., 2010</offsets></xref><offsets xml_i="15470" xml_f="16041" txt_i="7371" txt_f="7942">). Furthermore, no clinical trials have explored probiotics and prebiotics alone and in combination to assess their potential synergistic benefits for metabolic health. Therefore, we conducted a double-blind, randomized, placebo-controlled, multi-center clinical trial adhering to the GCP principles to investigate the effects of a probiotic (B420) and a prebiotic (LU) on weight management and an extensive panel of mechanistic parameters, including markers of low-grade inflammation, adipose tissue metabolism, bacterial translocation and fecal short-chain fatty acids.</offsets></p></sec><sec id="s0010"><label><offsets xml_i="16074" xml_f="16075" txt_i="7944" txt_f="7945">2</offsets></label><title><offsets xml_i="16090" xml_f="16111" txt_i="7945" txt_f="7966">Materials and Methods</offsets></title><p><offsets xml_i="16122" xml_f="16779" txt_i="7967" txt_f="8624">This double-blind, randomized, parallel, placebo-controlled clinical trial was conducted in four clinical research centers in southern Finland: VL-Medi Oy (Helsinki), Clinical Research Services Turku (Turku), FinnMedi Oy (Tampere) and Kerava Health Care Center (Kerava). All research procedures performed in this trial were in strict accordance with a pre-defined protocol, and adhered to international GCP guidelines and the Declaration of Helsinki. The study was approved by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa and all participants signed informed consent prior to participation. This study is registered in </offsets><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="ir0015"><offsets xml_i="16860" xml_f="16878" txt_i="8624" txt_f="8642">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="16889" xml_f="16910" txt_i="8642" txt_f="8663"> with the identifier </offsets><ext-link ext-link-type="uri" xlink:href="ctgov:NCT01978691" id="ir0020"><offsets xml_i="16983" xml_f="16994" txt_i="8663" txt_f="8674">NCT01978691</offsets></ext-link><offsets xml_i="17005" xml_f="17006" txt_i="8674" txt_f="8675">.</offsets></p><sec id="s0015"><label><offsets xml_i="17033" xml_f="17036" txt_i="8676" txt_f="8679">2.1</offsets></label><title><offsets xml_i="17051" xml_f="17063" txt_i="8679" txt_f="8691">Participants</offsets></title><p><offsets xml_i="17074" xml_f="17232" txt_i="8692" txt_f="8850">Eligible participants were 18–65 years old with a body mass index (BMI) between 28.0–34.9 and a waist to hip ratio of ≥ 0.88 for males and ≥ 0.83 for females.</offsets></p><p><offsets xml_i="17239" xml_f="17536" txt_i="8851" txt_f="9148">Exclusion criteria were, briefly: diagnosed type 1 or type 2 diabetes or cardiovascular disease, or use of related medication; use of laxatives, fiber supplements or probiotics in the previous 6 weeks; inflammatory disorders and use of immunomodulatory drugs; history of bariatric surgery; use of </offsets><italic><offsets xml_i="17544" xml_f="17548" txt_i="9148" txt_f="9152">anti</offsets></italic><offsets xml_i="17557" xml_f="17959" txt_i="9152" txt_f="9554">-obesity drugs in the previous 3 months; recent (last 2 months) or on-going antibiotic use; excessive use of vitamin D supplementation; active or recent (last 3 months) participation in a weight loss program or weight change of 3 kg during the past 3 months; pregnant or planning pregnancy within 6 months or breastfeeding women; drug or alcohol abuse; and other reasons identified by the Investigator.</offsets></p></sec><sec id="s0020"><label><offsets xml_i="17992" xml_f="17995" txt_i="9556" txt_f="9559">2.2</offsets></label><title><offsets xml_i="18010" xml_f="18048" txt_i="9559" txt_f="9597">Intervention, Compliance and Stability</offsets></title><p><offsets xml_i="18059" xml_f="18237" txt_i="9598" txt_f="9776">All study products were obtained from DuPont Nutrition and Health (Madison, WI, USA) in sachets. The study arms were: 1) Placebo, microcrystalline cellulose 12 g/day; 2) B420, 10</offsets><sup><offsets xml_i="18242" xml_f="18244" txt_i="9776" txt_f="9778">10</offsets></sup><offsets xml_i="18250" xml_f="18337" txt_i="9778" txt_f="9865"> CFU/day in 12 g of microcrystalline cellulose (B420); 3) LU, 12 g/day; and 4) B420, 10</offsets><sup><offsets xml_i="18342" xml_f="18344" txt_i="9865" txt_f="9867">10</offsets></sup><offsets xml_i="18350" xml_f="18934" txt_i="9867" txt_f="10451"> CFU/day in 12 g of LU (LU + B420). Microcrystalline cellulose was chosen as placebo because it contains virtually no energy and is less fermented by gut microbes than alternative dietary fibers. Participants were provided with commercially available fruit smoothie products and instructed to mix the contents of one sachet into a 250 ml bottle of smoothie (130 kcal) each day while otherwise maintaining their regular diet. The smoothies were provided to the subjects to mask subtle differences in the study products and to standardize the matrix in which the products were consumed.</offsets></p><p><offsets xml_i="18941" xml_f="19372" txt_i="10452" txt_f="10883">Following separate visits for screening and baseline assessments, participants used the study product for six months, during which they came for clinic visits at 2 months, 4 months and 6 months, with in-between telephone contacts to track compliance and potential adverse events. After completing the intervention, participants came for one more follow-up clinic visit one month after the end of the dietary intervention (month 7).</offsets></p><p><offsets xml_i="19379" xml_f="20188" txt_i="10884" txt_f="11693">Compliance was monitored with three different methods: 1) Participants were asked to report product intake on a specific check-list, 2) Participants were asked to return all used and unused sachets to the site to count the number of opened sachets per the number of treatment days, and 3) Fecal samples were analyzed for the presence of B420 with qPCR from all participant who returned a fecal sample at the six-month visit. Details of the qPCR detection procedures are reported in the Supplemental Materials and Methods. In the Intention-to-Treat (ITT) population, the average calculated compliance (method 2) was 86% across groups, while in the B420 and LU + B420 groups the bacterial strain was detected in the feces of 82% of participants. The primers used for qPCR were also able to detect certain other </offsets><italic><offsets xml_i="20196" xml_f="20220" txt_i="11693" txt_f="11717">Bifidobacterium animalis</offsets></italic><offsets xml_i="20229" xml_f="20235" txt_i="11717" txt_f="11723"> ssp. </offsets><italic><offsets xml_i="20243" xml_f="20249" txt_i="11723" txt_f="11729">lactis</offsets></italic><offsets xml_i="20258" xml_f="20434" txt_i="11729" txt_f="11905"> strains such as HN019, Bl-04 and Bi-07, but not Bb12. Four participants (8%) in the Placebo group and seven (15%) in the LU group tested positive in the qPCR assay (Table S1).</offsets></p><p><offsets xml_i="20441" xml_f="20553" txt_i="11906" txt_f="12018">Product stability was monitored throughout the study. The minimum target activity for B420 was planned at 1 × 10</offsets><sup><offsets xml_i="20558" xml_f="20560" txt_i="12018" txt_f="12020">10</offsets></sup><offsets xml_i="20566" xml_f="20630" txt_i="12020" txt_f="12084"> CFU/day. The dose of B420 at the time of packaging was 1.4 × 10</offsets><sup><offsets xml_i="20635" xml_f="20637" txt_i="12084" txt_f="12086">10</offsets></sup><offsets xml_i="20643" xml_f="20682" txt_i="12086" txt_f="12125"> CFU/day in the B420 group and 1.3 × 10</offsets><sup><offsets xml_i="20687" xml_f="20689" txt_i="12125" txt_f="12127">10</offsets></sup><offsets xml_i="20695" xml_f="20928" txt_i="12127" txt_f="12360"> CFU/day in the LU + B420 group to account for loss of stability during the study. Sachets returned from the study participants were re-tested for probiotic cell count at the end of the study with the following results: B420 1.1 × 10</offsets><sup><offsets xml_i="20933" xml_f="20935" txt_i="12360" txt_f="12362">10</offsets></sup><offsets xml_i="20941" xml_f="20973" txt_i="12362" txt_f="12394"> CFU/day, and LU + B420 1.1 × 10</offsets><sup><offsets xml_i="20978" xml_f="20980" txt_i="12394" txt_f="12396">10</offsets></sup><offsets xml_i="20986" xml_f="21114" txt_i="12396" txt_f="12524"> CFU/day, demonstrating excellent stability of the study probiotic. There were no contaminations in the Placebo and LU products.</offsets></p></sec><sec id="s0025"><label><offsets xml_i="21147" xml_f="21150" txt_i="12526" txt_f="12529">2.3</offsets></label><title><offsets xml_i="21165" xml_f="21198" txt_i="12529" txt_f="12562">Body Composition-Related Outcomes</offsets></title><p><offsets xml_i="21209" xml_f="21782" txt_i="12563" txt_f="13136">The pre-defined primary outcome of the present study was the relative change in body fat mass from baseline to end-of-treatment (6 months). Body fat mass was measured with a dual-energy X-ray absorptiometry (DEXA) scan at qualified private medical centers. In addition, body fat mass and lean body mass were recorded as total and from individual regions of the body (android, gynoid, trunk, legs, arms). Other obesity-related outcomes included body weight and waist and hip circumference, which were measured with calibrated weighing scales and tape measures, respectively.</offsets></p></sec><sec id="s0030"><label><offsets xml_i="21815" xml_f="21818" txt_i="13138" txt_f="13141">2.4</offsets></label><title><offsets xml_i="21833" xml_f="21861" txt_i="13141" txt_f="13169">Clinical Laboratory Outcomes</offsets></title><p><offsets xml_i="21872" xml_f="22619" txt_i="13170" txt_f="13917">At the clinic visits (baseline, 2 months, 4 months, 6 months and follow-up), blood was drawn in the morning from fasting participants and sent from all sites to a certified central laboratory (United Medix Laboratories, Finland) for analysis of serum high-sensitivity C-reactive protein (hsCRP), serum glucose, serum insulin, blood glycosylated hemoglobin (HbA1c), serum lipids (total cholesterol, LDL, HDL and triglycerides) and serum cortisol. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated from fasting glucose and insulin levels ([glucose in mmol/l] * [insulin in mU/l] / 22.5). Serum liver markers (ASAT, ALAT, gamma-glutamyltransferase) were also analyzed at the central laboratory to monitor product safety.</offsets></p></sec><sec id="s0035"><label><offsets xml_i="22652" xml_f="22655" txt_i="13919" txt_f="13922">2.5</offsets></label><title><offsets xml_i="22670" xml_f="22701" txt_i="13922" txt_f="13953">Exploratory Laboratory Outcomes</offsets></title><p><offsets xml_i="22712" xml_f="22985" txt_i="13954" txt_f="14227">The following blood biomarkers were analyzed with ELISA: interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), interleukin-1beta (IL-1β), plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion protein 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), </offsets><italic><offsets xml_i="22993" xml_f="22994" txt_i="14227" txt_f="14228">E</offsets></italic><offsets xml_i="23003" xml_f="23322" txt_i="14228" txt_f="14547">-selectin, sCD14, leptin, monocyte chemoattractant protein 1 (MCP-1), adiponectin, zonulin, angiopoietin-like protein 4 (angptl4), oxidized LDL cholesterol (oxLDL) and ApoB-48. The employed assay kits and their performance characteristics (coefficients of variation) are detailed in Supplementary Materials and Methods.</offsets></p><p><offsets xml_i="23329" xml_f="23582" txt_i="14548" txt_f="14801">For lipopolysaccharide (LPS) analyses, serum samples were diluted 1:100, heat-treated for 45 min at 60 °C, and assayed in triplicate using the Limulus Amebocyte Lysate (LAL) kinetic chromogenic method (Charles River). The quantitation limit was 48 EU/l.</offsets></p></sec><sec id="s0040"><label><offsets xml_i="23615" xml_f="23618" txt_i="14803" txt_f="14806">2.6</offsets></label><title><offsets xml_i="23633" xml_f="23690" txt_i="14806" txt_f="14863">Analysis of Acidic Fermentation Products in Fecal Samples</offsets></title><p><offsets xml_i="23701" xml_f="23831" txt_i="14864" txt_f="14994">Fecal short-chain fatty acids (SCFA) were analyzed with gas chromatography, as detailed in the Supplemental Materials and Methods.</offsets></p></sec><sec id="s0045"><label><offsets xml_i="23864" xml_f="23867" txt_i="14996" txt_f="14999">2.7</offsets></label><title><offsets xml_i="23882" xml_f="23919" txt_i="14999" txt_f="15036">Food Intake and Exercise Measurements</offsets></title><p><offsets xml_i="23930" xml_f="24090" txt_i="15037" txt_f="15197">Food intake was measured with a 5-day food diary at baseline, 2 months and 6 months (end of intervention) as detailed in the Supplemental Materials and Methods.</offsets></p><p><offsets xml_i="24097" xml_f="24248" txt_i="15198" txt_f="15349">Habitual exercise was captured with a simple three-point questionnaire and calculated into metabolic equivalents (MET h/day), as previously described (</offsets><xref rid="bb0095" ref-type="bibr"><offsets xml_i="24283" xml_f="24302" txt_i="15349" txt_f="15368">Kujala et al., 1998</offsets></xref><offsets xml_i="24309" xml_f="24311" txt_i="15368" txt_f="15370">).</offsets></p></sec><sec id="s0050"><label><offsets xml_i="24344" xml_f="24347" txt_i="15372" txt_f="15375">2.8</offsets></label><title><offsets xml_i="24362" xml_f="24376" txt_i="15375" txt_f="15389">Adverse Events</offsets></title><p><offsets xml_i="24387" xml_f="24741" txt_i="15390" txt_f="15744">Investigators asked study participants about adverse events at every study visit. All possible adverse events were recorded and coded according to MedDRA. The adverse events were classified by the Investigator according to severity (mild, moderate, severe) and possible relationship to treatment (unrelated, unlikely, possible, probable, not assessable).</offsets></p></sec><sec id="s0055"><label><offsets xml_i="24774" xml_f="24777" txt_i="15746" txt_f="15749">2.9</offsets></label><title><offsets xml_i="24792" xml_f="24817" txt_i="15749" txt_f="15774">Sample Size Determination</offsets></title><p><offsets xml_i="24828" xml_f="25654" txt_i="15775" txt_f="16601">A one-way analysis of covariance (ANCOVA) was used to analyze the primary outcome, with baseline body fat mass as covariate. The mean relative change from baseline to 6 months in body fat mass was assumed to be 1% in the active treatment groups compared to the placebo group, and the common standard deviation was expected to be 2%. With these assumptions, 43 participants per group (172 in total) was calculated to give above 80% power to reject a null hypothesis of no difference between the active treatments compared to placebo with a one-way ANOVA, using a 5% level of significance. The power for the ANCOVA model was expected to be similar or slightly higher than for an ANOVA model. In order to compensate for an expected drop-out rate of approximately 23.5%, a total of 225 participants were randomized into the study.</offsets></p></sec><sec id="s0060"><label><offsets xml_i="25687" xml_f="25691" txt_i="16603" txt_f="16607">2.10</offsets></label><title><offsets xml_i="25706" xml_f="25732" txt_i="16607" txt_f="16633">Randomization and Blinding</offsets></title><p><offsets xml_i="25743" xml_f="26706" txt_i="16634" txt_f="17597">The randomization scheme (1:1:1:1 allocation) was generated using a computerized procedure into blocks of four randomization codes each. Boxes of investigational product were labeled with the corresponding randomization code and study centers were advised to always use the smallest available randomization code and corresponding study product. The randomization code was generated by the contract research organization Smerud Medical Research Finland Ab Oy (Kirkkonummi, Finland). The participants, the site personnel, the study monitor, the statistician and sponsor's representatives were all blinded to the randomization until the end of the intervention phase, when all data for primary and secondary outcomes, adverse events and compliance had been collected and validated. The study populations were defined prior to breaking the treatment code. Exploratory outcomes were assayed in a blinded fashion, but were not included in the blind data review process.</offsets></p></sec><sec id="s0065"><label><offsets xml_i="26739" xml_f="26743" txt_i="17599" txt_f="17603">2.11</offsets></label><title><offsets xml_i="26758" xml_f="26777" txt_i="17603" txt_f="17622">Statistical Methods</offsets></title><p><offsets xml_i="26788" xml_f="27492" txt_i="17623" txt_f="18327">The primary and pre-determined statistical analysis was an ANCOVA to compare changes from baseline to end-of-intervention. Baseline values were used as covariates when they were significant in the model. For the ITT population, the last observation was carried forward for missing observations. All group-wise comparisons were performed using Dunnett's adjustment for multiple testing. A factorial analysis (two-way ANCOVA) was conducted post-hoc after unblinding, because of the lower number of participants in the B420 group compared to the other groups. There was no apparent reason for the higher number of exclusions in the B420 group, since the reasons for exclusion were similar across all groups.</offsets></p><p><offsets xml_i="27499" xml_f="27931" txt_i="18328" txt_f="18760">Data for LPS, hsCRP and IL-6 were considered non-normally distributed. Data for hsCRP and IL-6 were analyzed with ANCOVA and Dunnett's adjustment after log-transformation. Data for LPS were analyzed with the Kruskal-Wallis test, with Dwass, Steel, Critchlow-Fligner analysis of between-group comparisons. Correlations between changes from baseline to end-of-study for the different markers were calculated with Spearman correlation.</offsets></p><p><offsets xml_i="27938" xml_f="28017" txt_i="18761" txt_f="18840">All data were analyzed with SAS version 9.3 using a significance level of 0.05.</offsets></p></sec></sec><sec id="s0070"><label><offsets xml_i="28056" xml_f="28057" txt_i="18843" txt_f="18844">3</offsets></label><title><offsets xml_i="28072" xml_f="28079" txt_i="18844" txt_f="18851">Results</offsets></title><sec id="s0075"><label><offsets xml_i="28110" xml_f="28113" txt_i="18852" txt_f="18855">3.1</offsets></label><title><offsets xml_i="28128" xml_f="28160" txt_i="18855" txt_f="18887">Recruitment and Participant Flow</offsets></title><p><offsets xml_i="28171" xml_f="28550" txt_i="18888" txt_f="19267">All 225 participants were randomized at four centers in southern Finland between December 2013 and October 2014, and the last participant completed the last follow-up visit in May 2015. Study participants were randomized to four groups for a six-month intervention and a one-month follow-up period: 1) Placebo, 12 g/day of microcrystalline cellulose; 2) LU, 12 g/day; 3) B420, 10</offsets><sup><offsets xml_i="28555" xml_f="28557" txt_i="19267" txt_f="19269">10</offsets></sup><offsets xml_i="28563" xml_f="28648" txt_i="19269" txt_f="19354"> Colony Forming Units (CFU) /day in 12 g microcrystalline cellulose; 4) LU + B420, 10</offsets><sup><offsets xml_i="28653" xml_f="28655" txt_i="19354" txt_f="19356">10</offsets></sup><offsets xml_i="28661" xml_f="28693" txt_i="19356" txt_f="19388"> CFU/day of B420 in 12 g/day LU.</offsets></p><p><offsets xml_i="28700" xml_f="28762" txt_i="19389" txt_f="19451">The study populations and reasons for exclusions are shown in </offsets><xref rid="f0005" ref-type="fig"><offsets xml_i="28795" xml_f="28801" txt_i="19451" txt_f="19457">Fig. 1</offsets></xref><offsets xml_i="28808" xml_f="30078" txt_i="19457" txt_f="20721">. Of the 225 randomized participants, the Investigator excluded one person from the study due to very high cholesterol levels, before the participant had taken any study product. Therefore, the total population analyzed for adverse events included 224 participants. The ITT population contained all 209 participants who were analyzed for any variable after the baseline visit, whereas the Per Protocol (PP) population included, as defined in the protocol, all 134 participants who completed the study without major protocol violations and who had at least more than one study visit completed. A Blind Data Review process prior to unblinding the study detailed the major protocol violations as follows: 1) &lt; 80% of study product compliance or &gt; 7 consecutive days of non-compliance; 2) Baseline or 6-month visit not completed; 3) Participant randomized against inclusion and exclusion criteria (e.g. use of high-dose vitamin D supplements); and 4) Use of systemic antibiotics during the intervention period. In addition, three participants were excluded from the PP population for body composition measurements for not completing the measurement within ten days after discontinuing treatment. None of the participants were reallocated to another group for analysis.</offsets></p><p><offsets xml_i="30085" xml_f="30145" txt_i="20722" txt_f="20782">The demographics of the ITT and PP populations are shown in </offsets><xref rid="t0005" ref-type="table"><offsets xml_i="30180" xml_f="30187" txt_i="20782" txt_f="20789">Table 1</offsets></xref><offsets xml_i="30194" xml_f="30657" txt_i="20789" txt_f="21252"> and were similar among the different treatment groups. Statistical conclusions for the ITT and PP populations differed greatly, and therefore drop-outs and protocol violations—which are common especially in long intervention studies such as this—were considered to have a significant impact on the outcomes. Consequently, the present report is mainly focused on the protocol-compliant PP population. Main outcomes for the ITT population can be found in Table S2.</offsets></p></sec><sec id="s0080"><label><offsets xml_i="30690" xml_f="30693" txt_i="21254" txt_f="21257">3.2</offsets></label><title><offsets xml_i="30708" xml_f="30744" txt_i="21257" txt_f="21293">Adverse Events and Safety Parameters</offsets></title><p><offsets xml_i="30755" xml_f="30992" txt_i="21294" txt_f="21531">All symptoms occurring during the study were documented and rated for severity and potential relationship with the study products. There were no major differences in the distribution of adverse events across groups. Over the course of 7 </offsets></p></sec><sec id="s0085"><label><offsets xml_i="31025" xml_f="31028" txt_i="21533" txt_f="21536">3.3</offsets></label><title><offsets xml_i="31043" xml_f="31147" txt_i="21536" txt_f="21640">B420 with or without LU Controls Body and Trunk Fat Mass, and Show Synergistic Effects on Lean Body Mass</offsets></title><p><offsets xml_i="31158" xml_f="31578" txt_i="21641" txt_f="22061">The primary outcome of this study was the relative change in body fat mass from baseline to the end of the intervention period (6 months). Body composition was measured with DEXA every two months during the intervention and at the follow-up after one month. In the ITT population, there were no statistically significant differences between the active treatment groups and Placebo in the changes in total body fat mass (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="31611" xml_f="31617" txt_i="22061" txt_f="22067">Fig. 2</offsets></xref><offsets xml_i="31624" xml_f="31768" txt_i="22067" txt_f="22211">A). In the PP population, however, the LU + B420 group showed a significant reduction in the change in total body fat mass compared to Placebo (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="31801" xml_f="31807" txt_i="22211" txt_f="22217">Fig. 2</offsets></xref><offsets xml_i="31814" xml_f="31972" txt_i="22217" txt_f="22375">B), resulting in an average difference of 1.4 kg in total body fat between the groups. The effect seemed to persist throughout the one-month wash-out period (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="32005" xml_f="32011" txt_i="22375" txt_f="22381">Fig. 2</offsets></xref><offsets xml_i="32018" xml_f="32191" txt_i="22381" txt_f="22554">C). The difference in body fat mass was most noticeable in the trunk area and demonstrated a similar, although non-significant pattern in the abdominal (i.e. android) area (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="32224" xml_f="32230" txt_i="22554" txt_f="22560">Fig. 2</offsets></xref><offsets xml_i="32237" xml_f="32818" txt_i="22560" txt_f="23141">D–E). In other regions of the body LU + B420 had no effect. LU and B420 (alone) were not statistically different from Placebo in any of the above mentioned variables. For absolute values in all measured areas of the body in the PP population, please refer to Table S4. Changes in total body fat mass per the following subgroups are shown in Fig. S1: men vs. women, low vs. high baseline fat intake, and those in the ITT population who used systemic antimicrobials during the study. Markers of glucose metabolism are presented in Table S5, and cardiovascular biomarkers in Table S6.</offsets></p><p><offsets xml_i="32825" xml_f="32888" txt_i="23142" txt_f="23205">Because of the lower number of observations in the B420 group (</offsets><italic><offsets xml_i="32896" xml_f="32897" txt_i="23205" txt_f="23206">n</offsets></italic><offsets xml_i="32906" xml_f="32943" txt_i="23206" txt_f="23243"> = 24) compared to the other groups (</offsets><italic><offsets xml_i="32951" xml_f="32952" txt_i="23243" txt_f="23244">n</offsets></italic><offsets xml_i="32961" xml_f="33231" txt_i="23244" txt_f="23514"> = 35–37), we decided to conduct a post-hoc factorial analysis to evaluate the independent effects of B420 and LU in the PP population. In the PP population, there were significant differences between the B420 and Placebo groups in their changes in total body fat mass (</offsets><italic><offsets xml_i="33239" xml_f="33240" txt_i="23514" txt_f="23515">P</offsets></italic><offsets xml_i="33249" xml_f="33276" txt_i="23515" txt_f="23542"> = 0.002), trunk fat mass (</offsets><italic><offsets xml_i="33284" xml_f="33285" txt_i="23542" txt_f="23543">P</offsets></italic><offsets xml_i="33294" xml_f="33327" txt_i="23543" txt_f="23576"> = 0.0002) and android fat mass (</offsets><italic><offsets xml_i="33335" xml_f="33336" txt_i="23576" txt_f="23577">P</offsets></italic><offsets xml_i="33345" xml_f="33524" txt_i="23577" txt_f="23756"> = 0.004), indicating that the probiotic itself could be effective for controlling fat mass, especially in the abdominal region. LU had no independent effects on these parameters.</offsets></p><p><offsets xml_i="33531" xml_f="33798" txt_i="23757" txt_f="24024">In addition, the results for lean body mass suggested synergy between the two investigational products, LU and B420. Although neither of the products alone had an effect on lean body mass, their combination significantly increased lean body mass compared to Placebo (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="33831" xml_f="33837" txt_i="24024" txt_f="24030">Fig. 2</offsets></xref><offsets xml_i="33844" xml_f="34008" txt_i="24030" txt_f="24194">F), and the difference developed as a gradual increase from baseline, although there were no changes in the physical exercise habits in any of the groups (Fig. S2).</offsets></p></sec><sec id="s0090"><label><offsets xml_i="34041" xml_f="34044" txt_i="24196" txt_f="24199">3.4</offsets></label><title><offsets xml_i="34059" xml_f="34130" txt_i="24199" txt_f="24270">B420 With or Without LU Reduces Waist Circumference Compared to Placebo</offsets></title><p><offsets xml_i="34141" xml_f="34229" txt_i="24271" txt_f="24359">The differences in body fat mass outcomes were not completely reflected in body weight (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="34262" xml_f="34268" txt_i="24359" txt_f="24365">Fig. 2</offsets></xref><offsets xml_i="34275" xml_f="34361" txt_i="24365" txt_f="24451">G). In fact, only the B420 group showed any trend towards a reduction in body weight (</offsets><italic><offsets xml_i="34369" xml_f="34370" txt_i="24451" txt_f="24452">P</offsets></italic><offsets xml_i="34379" xml_f="34597" txt_i="24452" txt_f="24670"> = 0.15) in the PP population, whereas in the LU + B420 group, the reduction in body fat mass was counterbalanced with an increase in lean body mass. In the factorial analysis, there was a significant effect for B420 (</offsets><italic><offsets xml_i="34605" xml_f="34606" txt_i="24670" txt_f="24671">P</offsets></italic><offsets xml_i="34615" xml_f="34647" txt_i="24671" txt_f="24703"> = 0.03), but no effect for LU (</offsets><italic><offsets xml_i="34655" xml_f="34656" txt_i="24703" txt_f="24704">P</offsets></italic><offsets xml_i="34665" xml_f="34798" txt_i="24704" txt_f="24837"> = 0.80) compared to placebo in the PP population. The LU + B420 group also showed a 2.7% (2.6 cm) reduction in waist circumference (</offsets><italic><offsets xml_i="34806" xml_f="34807" txt_i="24837" txt_f="24838">P</offsets></italic><offsets xml_i="34816" xml_f="34827" txt_i="24838" txt_f="24849"> = 0.047) (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="34860" xml_f="34866" txt_i="24849" txt_f="24855">Fig. 2</offsets></xref><offsets xml_i="34873" xml_f="34889" txt_i="24855" txt_f="24871">H) and a trend (</offsets><italic><offsets xml_i="34897" xml_f="34898" txt_i="24871" txt_f="24872">P</offsets></italic><offsets xml_i="34907" xml_f="34988" txt_i="24872" txt_f="24953"> = 0.079) towards a 1.3% (1.4 cm) smaller hip circumference compared to Placebo (</offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="35021" xml_f="35027" txt_i="24953" txt_f="24959">Fig. 2</offsets></xref><offsets xml_i="35034" xml_f="35209" txt_i="24959" txt_f="25134">I). According to the factorial analysis, there was a significant 2.4% difference in the change in waist circumference between B420 and Placebo (− 2.4 cm compared to Placebo) (</offsets><italic><offsets xml_i="35217" xml_f="35218" txt_i="25134" txt_f="25135">P</offsets></italic><offsets xml_i="35227" xml_f="35237" txt_i="25135" txt_f="25145"> = 0.004).</offsets></p></sec><sec id="s0095"><label><offsets xml_i="35270" xml_f="35273" txt_i="25147" txt_f="25150">3.5</offsets></label><title><offsets xml_i="35288" xml_f="35379" txt_i="25150" txt_f="25241">Six-Month Supplementation with B420 and LU + B420 Reduces Energy Intake Compared to Placebo</offsets></title><p><offsets xml_i="35390" xml_f="35687" txt_i="25242" txt_f="25539">We measured dietary intake with 5-day food diaries at baseline and at 2 and 6 months after study start. There were no differences between the groups in baseline dietary intake (Table S7). B420 and LU + B420 reduced energy intake by approximately 300 kcal/day and 210 kcal/day compared to Placebo (</offsets><xref rid="t0010" ref-type="table"><offsets xml_i="35722" xml_f="35729" txt_i="25539" txt_f="25546">Table 2</offsets></xref><offsets xml_i="35736" xml_f="35895" txt_i="25546" txt_f="25705">). This was associated with a reduced intake of dietary fat and fiber in the B420 group, but without differences in the relative proportion of fat in the diet.</offsets></p><p><offsets xml_i="35902" xml_f="36039" txt_i="25706" txt_f="25843">B420 also increased plasma cortisol concentrations (Fig. S3), which has been suggested to increase energy expenditure and fat oxidation (</offsets><xref rid="bb0010" ref-type="bibr"><offsets xml_i="36074" xml_f="36094" txt_i="25843" txt_f="25863">Brillon et al., 1995</offsets></xref><offsets xml_i="36101" xml_f="36210" txt_i="25863" txt_f="25972">) and to suppress inflammation. Increased plasma cortisol may also be related to an adverse stress response (</offsets><xref rid="bb0245" ref-type="bibr"><offsets xml_i="36245" xml_f="36266" txt_i="25972" txt_f="25993">Zunszain et al., 2011</offsets></xref><offsets xml_i="36273" xml_f="36522" txt_i="25993" txt_f="26242">), however, there was only one psychiatric-related adverse event in the B420 group: a mild worsening of depression, which also occurred in one participant in the Placebo group. The investigator evaluated both cases as unrelated to the study product.</offsets></p></sec><sec id="s0100"><label><offsets xml_i="36555" xml_f="36558" txt_i="26244" txt_f="26247">3.6</offsets></label><title><offsets xml_i="36573" xml_f="36637" txt_i="26247" txt_f="26311">Changes in Fat Mass Correlate with Circulating Zonulin and hsCRP</offsets></title><p><offsets xml_i="36648" xml_f="36726" txt_i="26312" txt_f="26390">Levels of circulating zonulin, a potential marker of intestinal permeability (</offsets><xref rid="bb0035" ref-type="bibr"><offsets xml_i="36761" xml_f="36780" txt_i="26390" txt_f="26409">Fasano et al., 2000</offsets></xref><offsets xml_i="36787" xml_f="36789" txt_i="26409" txt_f="26411">, </offsets><xref rid="bb0130" ref-type="bibr"><offsets xml_i="36824" xml_f="36853" txt_i="26411" txt_f="26440">Moreno-Navarrete et al., 2012</offsets></xref><offsets xml_i="36860" xml_f="36981" txt_i="26440" txt_f="26561">), seemed to remain consistently lower throughout the study in the B420 and LU + B420 groups compared to Placebo and LU (</offsets><xref rid="f0015" ref-type="fig"><offsets xml_i="37014" xml_f="37020" txt_i="26561" txt_f="26567">Fig. 3</offsets></xref><offsets xml_i="37027" xml_f="37135" txt_i="26567" txt_f="26675">A), which was reflected as a trend towards a difference between B420 and Placebo in the factorial analysis (</offsets><italic><offsets xml_i="37143" xml_f="37144" txt_i="26675" txt_f="26676">P</offsets></italic><offsets xml_i="37153" xml_f="37164" txt_i="26676" txt_f="26687"> = 0.063) (</offsets><xref rid="t0015" ref-type="table"><offsets xml_i="37199" xml_f="37206" txt_i="26687" txt_f="26694">Table 3</offsets></xref><offsets xml_i="37213" xml_f="37316" txt_i="26694" txt_f="26797">). Changes in zonulin were also statistically significantly correlated with changes in trunk fat mass (</offsets><italic><offsets xml_i="37324" xml_f="37325" txt_i="26797" txt_f="26798">r</offsets></italic><offsets xml_i="37334" xml_f="37344" txt_i="26798" txt_f="26808"> = 0.349, </offsets><italic><offsets xml_i="37352" xml_f="37353" txt_i="26808" txt_f="26809">P</offsets></italic><offsets xml_i="37362" xml_f="37377" txt_i="26809" txt_f="26821"> &lt; 0.0001) (</offsets><xref rid="f0015" ref-type="fig"><offsets xml_i="37410" xml_f="37416" txt_i="26821" txt_f="26827">Fig. 3</offsets></xref><offsets xml_i="37423" xml_f="37541" txt_i="26827" txt_f="26945">B), indicating a potential mechanistic link between the two. This correlation was only evident in the LU + B420 group.</offsets></p><p><offsets xml_i="37548" xml_f="37614" txt_i="26946" txt_f="27012">Changes in hsCRP were somewhat similar to the changes in zonulin (</offsets><xref rid="f0015" ref-type="fig"><offsets xml_i="37647" xml_f="37653" txt_i="27012" txt_f="27018">Fig. 3</offsets></xref><offsets xml_i="37660" xml_f="37828" txt_i="27018" txt_f="27186">C). Although there were no differences between groups in the primary analysis, a factorial analysis showed a tendency towards a reduction in hsCRP in B420 vs. Placebo (</offsets><italic><offsets xml_i="37836" xml_f="37837" txt_i="27186" txt_f="27187">P</offsets></italic><offsets xml_i="37846" xml_f="37857" txt_i="27187" txt_f="27198"> = 0.073) (</offsets><xref rid="t0015" ref-type="table"><offsets xml_i="37892" xml_f="37899" txt_i="27198" txt_f="27205">Table 3</offsets></xref><offsets xml_i="37906" xml_f="37993" txt_i="27205" txt_f="27292">). Changes in hsCRP were also significantly correlated with changes in trunk fat mass (</offsets><italic><offsets xml_i="38001" xml_f="38002" txt_i="27292" txt_f="27293">r</offsets></italic><offsets xml_i="38011" xml_f="38021" txt_i="27293" txt_f="27303"> = 0.217, </offsets><italic><offsets xml_i="38029" xml_f="38030" txt_i="27303" txt_f="27304">P</offsets></italic><offsets xml_i="38039" xml_f="38050" txt_i="27304" txt_f="27315"> = 0.012) (</offsets><xref rid="f0015" ref-type="fig"><offsets xml_i="38083" xml_f="38089" txt_i="27315" txt_f="27321">Fig. 3</offsets></xref><offsets xml_i="38096" xml_f="38237" txt_i="27321" txt_f="27462">D), but again only in the LU + B420 group. Changes in hsCRP were also significantly correlated with changes in zonulin (Spearman correlation </offsets><italic><offsets xml_i="38245" xml_f="38246" txt_i="27462" txt_f="27463">r</offsets></italic><offsets xml_i="38255" xml_f="38265" txt_i="27463" txt_f="27473"> = 0.199, </offsets><italic><offsets xml_i="38273" xml_f="38274" txt_i="27473" txt_f="27474">P</offsets></italic><offsets xml_i="38283" xml_f="38293" txt_i="27474" txt_f="27484"> = 0.021).</offsets></p><p><offsets xml_i="38300" xml_f="38387" txt_i="27485" txt_f="27572">LU + B420 appeared to increase LPS level in plasma compared to Placebo (Kruskal-Wallis </offsets><italic><offsets xml_i="38395" xml_f="38396" txt_i="27572" txt_f="27573">P</offsets></italic><offsets xml_i="38405" xml_f="38623" txt_i="27573" txt_f="27791"> = 0.009), although the changes were small and LPS level remained below or close to the detection limit in most participants. There was no effect on soluble cluster of differentiation 14 (sCD14), a co-receptor of LPS (</offsets><xref rid="t0015" ref-type="table"><offsets xml_i="38658" xml_f="38665" txt_i="27791" txt_f="27798">Table 3</offsets></xref><offsets xml_i="38672" xml_f="38806" txt_i="27798" txt_f="27932">), underlining the lack of inflammatory response to the slightly increased LPS levels. There were also no differences in IL-6 levels (</offsets><xref rid="t0015" ref-type="table"><offsets xml_i="38841" xml_f="38848" txt_i="27932" txt_f="27939">Table 3</offsets></xref><offsets xml_i="38855" xml_f="38978" txt_i="27939" txt_f="28062">). Concentrations of TNF-α and IL-1β were below the lower limit of quantitation in 95 and 97% of the samples, respectively.</offsets></p><p><offsets xml_i="38985" xml_f="39114" txt_i="28063" txt_f="28192">The corresponding outcomes for the ITT population are shown in Table S8. Adipose tissue-related biomarkers are shown in Table S9.</offsets></p></sec><sec id="s0105"><label><offsets xml_i="39147" xml_f="39150" txt_i="28194" txt_f="28197">3.7</offsets></label><title><offsets xml_i="39165" xml_f="39219" txt_i="28197" txt_f="28251">Increased Production of Bacterial Metabolites in Feces</offsets></title><p><offsets xml_i="39230" xml_f="39346" txt_i="28252" txt_f="28368">In the factorial analysis, B420 increased the concentration of fecal propionic acid, butyric acid and valeric acid (</offsets><italic><offsets xml_i="39354" xml_f="39355" txt_i="28368" txt_f="28369">P</offsets></italic><offsets xml_i="39364" xml_f="39377" txt_i="28369" txt_f="28379"> &lt; 0.05) (</offsets><xref rid="t0020" ref-type="table"><offsets xml_i="39412" xml_f="39419" txt_i="28379" txt_f="28386">Table 4</offsets></xref><offsets xml_i="39426" xml_f="39736" txt_i="28386" txt_f="28696">, data for ITT population shown in Table S10.), which indicated an increased metabolism of non-digestible polysaccharides and suggests changes in the composition of the gut microbiota. A tendency for similar changes was noted for acetic acid, although the factorial analysis was not statistically significant (</offsets><italic><offsets xml_i="39744" xml_f="39745" txt_i="28696" txt_f="28697">P</offsets></italic><offsets xml_i="39754" xml_f="40020" txt_i="28697" txt_f="28963"> = 0.13). In the primary statistical analysis, only valeric acid was significantly increased by B420; there were no other statistically significant differences between the groups. Total fecal SCFA concentrations were also increased by B420 in the factorial analysis.</offsets></p></sec></sec><sec id="s0110"><label><offsets xml_i="40059" xml_f="40060" txt_i="28966" txt_f="28967">4</offsets></label><title><offsets xml_i="40075" xml_f="40085" txt_i="28967" txt_f="28977">Discussion</offsets></title><p><offsets xml_i="40096" xml_f="40905" txt_i="28978" txt_f="29787">Over the past decade, advances in science have established a link between gut microbes and obesity, raising interest in developing probiotics and prebiotics for weight management. This study shows consistent results towards an improvement in weight management -related parameters in the probiotic and synbiotic groups, including total body fat mass, trunk fat mass, waist circumference, and energy intake in the Per Protocol population. Furthermore, our study demonstrates synergy between a probiotic and a prebiotic fiber supplement in promoting lean body mass accumulation. We also present results on biomarkers associated with gut barrier function, reduced inflammatory tone and intestinal microbiota metabolism that suggest a potential mechanism of action for B420 and LU + B420 in reducing body fat mass.</offsets></p><p><offsets xml_i="40912" xml_f="41012" txt_i="29788" txt_f="29888">We have previously shown that B420 reduces body fat mass gain in mice that are fed a high-fat diet (</offsets><xref rid="bb0200" ref-type="bibr"><offsets xml_i="41047" xml_f="41067" txt_i="29888" txt_f="29908">Stenman et al., 2014</offsets></xref><offsets xml_i="41074" xml_f="41545" txt_i="29908" txt_f="30379">). In the current study, only the LU + B420 group significantly reduced total body fat mass compared to Placebo in the PP population, while there were no differences in the ITT population. A post-hoc factorial analysis showed that B420 alone had a significant effect in both the ITT and PP population. The differences between the treatment groups were consistent across several outcomes, providing further support to the previous results obtained in experimental animals.</offsets></p><p><offsets xml_i="41552" xml_f="42343" txt_i="30380" txt_f="31171">We conducted statistical analyses on both, ITT and PP populations, with different conclusions. In the ITT populations we used for missing observations the Last Observation Carried Forward method that is a widely accepted approach, but can alter the conclusions of very long studies, which are prone to drop-outs and protocol violations. The findings of the PP population can be considered as being better representative of the effect of the investigated products, but they, in turn, are prone to bias from participant drop-outs. In this study, our PP population included 64% of the ITT population, mainly due to drop-outs, non-compliance and use of systemic antimicrobials. This weakens the statistical power in the PP population and warrants further studies to support the present findings.</offsets></p><p><offsets xml_i="42350" xml_f="42990" txt_i="31172" txt_f="31812">In the current study, the study participants in the Placebo group gained approximately 1 kg (1.1%) of weight compared to baseline. This weight gain was not due to increased energy intake from the smoothie vehicle, as energy intake did not change in the Placebo group (− 23 kcal). On the contrary, the LU + B420 and B420 groups showed considerable reductions in their energy intake (− 230 and − 320 kcal/day, respectively), while body weight and body fat mass did not differ from baseline, suggesting that B420 and LU + B420 normalized energy balance by reducing energy intake to a level that maintains, rather than increases, body fat mass.</offsets></p><p><offsets xml_i="42997" xml_f="43132" txt_i="31813" txt_f="31948">According to the Helsinki Health Study, steady weight gain over time is rather common among an average Finnish middle-aged population (</offsets><xref rid="bb0120" ref-type="bibr"><offsets xml_i="43167" xml_f="43185" txt_i="31948" txt_f="31966">Loman et al., 2013</offsets></xref><offsets xml_i="43192" xml_f="43433" txt_i="31966" txt_f="32207">), as approximately 30% gained at least 5 kg weight during a 5–7-year follow-up period. Our overweight and obese study population (BMI 28–34.5) may have been more prone to weight gain than the average population in the Helsinki Health Study.</offsets></p><p><offsets xml_i="43440" xml_f="43606" txt_i="32208" txt_f="32374">Four clinical studies involving healthy, overweight and/or obese participants have investigated the effects of micro-organisms on weight management or body fat mass (</offsets><xref rid="bb0070" ref-type="bibr"><offsets xml_i="43641" xml_f="43661" txt_i="32374" txt_f="32394">Kadooka et al., 2010</offsets></xref><offsets xml_i="43668" xml_f="43670" txt_i="32394" txt_f="32396">, </offsets><xref rid="bb0075" ref-type="bibr"><offsets xml_i="43705" xml_f="43725" txt_i="32396" txt_f="32416">Kadooka et al., 2013</offsets></xref><offsets xml_i="43732" xml_f="43734" txt_i="32416" txt_f="32418">, </offsets><xref rid="bb0125" ref-type="bibr"><offsets xml_i="43769" xml_f="43788" txt_i="32418" txt_f="32437">Minami et al., 2015</offsets></xref><offsets xml_i="43795" xml_f="43797" txt_i="32437" txt_f="32439">, </offsets><xref rid="bb0185" ref-type="bibr"><offsets xml_i="43832" xml_f="43852" txt_i="32439" txt_f="32459">Sanchez et al., 2014</offsets></xref><offsets xml_i="43859" xml_f="44028" txt_i="32459" txt_f="32628">). The effect size seen in the current study (6.7% difference in trunk fat between LU + B420 and Placebo) is quite comparable to that seen in 12-week interventions with </offsets><italic><offsets xml_i="44036" xml_f="44057" txt_i="32628" txt_f="32649">Lactobacillus gasseri</offsets></italic><offsets xml_i="44066" xml_f="44150" txt_i="32649" txt_f="32733"> SBT2055 where abdominal fat was reduced by approximately 4.5% compared to placebo (</offsets><xref rid="bb0070" ref-type="bibr"><offsets xml_i="44185" xml_f="44205" txt_i="32733" txt_f="32753">Kadooka et al., 2010</offsets></xref><offsets xml_i="44212" xml_f="44214" txt_i="32753" txt_f="32755">, </offsets><xref rid="bb0075" ref-type="bibr"><offsets xml_i="44249" xml_f="44269" txt_i="32755" txt_f="32775">Kadooka et al., 2013</offsets></xref><offsets xml_i="44276" xml_f="44455" txt_i="32775" txt_f="32954">). It is difficult to compare the employed statistical methodology, however, because it remains unclear which participants were included in the analyses. In comparison, intake of </offsets><italic><offsets xml_i="44463" xml_f="44484" txt_i="32954" txt_f="32975">Bifidobacterium breve</offsets></italic><offsets xml_i="44493" xml_f="44567" txt_i="32975" txt_f="33049"> B-3 reduced body fat mass by 0.6 kg compared to placebo within 12 weeks (</offsets><xref rid="bb0125" ref-type="bibr"><offsets xml_i="44602" xml_f="44621" txt_i="33049" txt_f="33068">Minami et al., 2015</offsets></xref><offsets xml_i="44628" xml_f="44784" txt_i="33068" txt_f="33224">). It should also be noted that the study participants in these three studies were Japanese whereas the present study was conducted on a Western population.</offsets></p><p><offsets xml_i="44791" xml_f="44840" txt_i="33225" txt_f="33274">In a Canadian study population, a combination of </offsets><italic><offsets xml_i="44848" xml_f="44871" txt_i="33274" txt_f="33297">Lactobacillus rhamnosus</offsets></italic><offsets xml_i="44880" xml_f="45068" txt_i="33297" txt_f="33485"> CGMCC1.3724 (LPR), inulin and oligofructose helped to further reduce weight (2.7 kg) and total body fat mass (1.8%) during a weight-loss and weight maintenance period, but only in women (</offsets><xref rid="bb0185" ref-type="bibr"><offsets xml_i="45103" xml_f="45123" txt_i="33485" txt_f="33505">Sanchez et al., 2014</offsets></xref><offsets xml_i="45130" xml_f="45236" txt_i="33505" txt_f="33611">). In the present study, we did not find marked differences between the observed effects in men and women.</offsets></p><p><offsets xml_i="45243" xml_f="45568" txt_i="33612" txt_f="33937">In terms of effect size, it is difficult to compare probiotics to pharmaceuticals, because the latter have been tested for weight loss instead of fat mass loss, and they are accompanied by a weight-loss program. However, the reported changes in body weight at six months compared to placebo have been: − 3.5 kg for orlistat (</offsets><xref rid="bb0220" ref-type="bibr"><offsets xml_i="45603" xml_f="45625" txt_i="33937" txt_f="33959">Torgerson et al., 2004</offsets></xref><offsets xml_i="45632" xml_f="45659" txt_i="33959" txt_f="33986">), − 5.5% for liraglutide (</offsets><xref rid="bb0160" ref-type="bibr"><offsets xml_i="45694" xml_f="45716" txt_i="33986" txt_f="34008">Pi-Sunyer et al., 2015</offsets></xref><offsets xml_i="45723" xml_f="45752" txt_i="34008" txt_f="34037">), and − 3.2% for locaserin (</offsets><xref rid="bb0135" ref-type="bibr"><offsets xml_i="45787" xml_f="45806" txt_i="34037" txt_f="34056">O'neil et al., 2012</offsets></xref><offsets xml_i="45813" xml_f="46252" txt_i="34056" txt_f="34495">), compared to − 1.4 kg (− 4.5%) with LU + B420 and − 1.0 kg (− 3.0%) with B420 in fat mass in the present study. It should be noted that probiotics are taken orally once per day, while orlistat is taken multiple times per day and liraglutide requires a daily subcutaneous injection. Therefore, probiotics and synbiotics could be a safe and convenient, non-pharmaceutical support for controlling body fat mass, especially prophylactically.</offsets></p><p><offsets xml_i="46259" xml_f="46626" txt_i="34496" txt_f="34863">The results of this study showed that changes in circulating zonulin levels correlated with changes in trunk fat mass, but only in the LU + B420 group, indicating a potential mechanistic relationship between zonulin and trunk fat mass. Also, B420 tended to reduce levels of circulating zonulin. Zonulin is the human analogue of the zonula occludens toxin produced by </offsets><italic><offsets xml_i="46634" xml_f="46648" txt_i="34863" txt_f="34877">Vibrio cholera</offsets></italic><offsets xml_i="46657" xml_f="46659" txt_i="34877" txt_f="34879"> (</offsets><xref rid="bb0235" ref-type="bibr"><offsets xml_i="46694" xml_f="46711" txt_i="34879" txt_f="34896">Wang et al., 2000</offsets></xref><offsets xml_i="46718" xml_f="46720" txt_i="34896" txt_f="34898">, </offsets><xref rid="bb0035" ref-type="bibr"><offsets xml_i="46755" xml_f="46774" txt_i="34898" txt_f="34917">Fasano et al., 2000</offsets></xref><offsets xml_i="46781" xml_f="46855" txt_i="34917" txt_f="34991">). It selectively increases intestinal permeability in jejunum and ileum (</offsets><xref rid="bb0235" ref-type="bibr"><offsets xml_i="46890" xml_f="46907" txt_i="34991" txt_f="35008">Wang et al., 2000</offsets></xref><offsets xml_i="46914" xml_f="46991" txt_i="35008" txt_f="35085">), and its release is induced by certain gut microbes, especially pathogens (</offsets><xref rid="bb0030" ref-type="bibr"><offsets xml_i="47026" xml_f="47047" txt_i="35085" txt_f="35106">El Asmar et al., 2002</offsets></xref><offsets xml_i="47054" xml_f="47176" txt_i="35106" txt_f="35228">), indicating that zonulin could act as a mechanistic link between changes in the gut microbiota and gut barrier function.</offsets></p><p><offsets xml_i="47183" xml_f="47264" txt_i="35229" txt_f="35310">When measured from circulation, zonulin has been linked with insulin resistance (</offsets><xref rid="bb0130" ref-type="bibr"><offsets xml_i="47299" xml_f="47328" txt_i="35310" txt_f="35339">Moreno-Navarrete et al., 2012</offsets></xref><offsets xml_i="47335" xml_f="47355" txt_i="35339" txt_f="35359">), type 2 diabetes (</offsets><xref rid="bb0240" ref-type="bibr"><offsets xml_i="47390" xml_f="47408" txt_i="35359" txt_f="35377">Zhang et al., 2014</offsets></xref><offsets xml_i="47415" xml_f="47430" txt_i="35377" txt_f="35392">), higher BMI (</offsets><xref rid="bb0130" ref-type="bibr"><offsets xml_i="47465" xml_f="47494" txt_i="35392" txt_f="35421">Moreno-Navarrete et al., 2012</offsets></xref><offsets xml_i="47501" xml_f="47542" txt_i="35421" txt_f="35462">) and non-alcoholic fatty liver disease (</offsets><xref rid="bb0145" ref-type="bibr"><offsets xml_i="47577" xml_f="47598" txt_i="35462" txt_f="35483">Pacifico et al., 2014</offsets></xref><offsets xml_i="47605" xml_f="47759" txt_i="35483" txt_f="35637">). The link between circulating zonulin and intestinal zonulin remains somewhat elusive, since circulating zonulin might not originate only from the gut (</offsets><xref rid="bb0235" ref-type="bibr"><offsets xml_i="47794" xml_f="47811" txt_i="35637" txt_f="35654">Wang et al., 2000</offsets></xref><offsets xml_i="47818" xml_f="47963" txt_i="35654" txt_f="35799">). Nevertheless, decreased circulating zonulin is associated with a decreased lactulose/mannitol ratio, an indicator of intestinal permeability (</offsets><xref rid="bb0180" ref-type="bibr"><offsets xml_i="47998" xml_f="48016" txt_i="35799" txt_f="35817">Russo et al., 2012</offsets></xref><offsets xml_i="48023" xml_f="48025" txt_i="35817" txt_f="35819">, </offsets><xref rid="bb0115" ref-type="bibr"><offsets xml_i="48060" xml_f="48076" txt_i="35819" txt_f="35835">Liu et al., 2013</offsets></xref><offsets xml_i="48083" xml_f="48142" txt_i="35835" txt_f="35894">), as well as fewer postoperative infection complications (</offsets><xref rid="bb0115" ref-type="bibr"><offsets xml_i="48177" xml_f="48193" txt_i="35894" txt_f="35910">Liu et al., 2013</offsets></xref><offsets xml_i="48200" xml_f="48363" txt_i="35910" txt_f="36073">). Furthermore, type 1 diabetic patients and their relatives were found to have increased circulating zonulin levels that correlated with intestinal permeability (</offsets><xref rid="bb0190" ref-type="bibr"><offsets xml_i="48398" xml_f="48417" txt_i="36073" txt_f="36092">Sapone et al., 2006</offsets></xref><offsets xml_i="48424" xml_f="48597" txt_i="36092" txt_f="36265">). According to these findings, it is plausible that the changes in circulating zonulin, as seen in the present study, are related to an improvement in gut barrier function.</offsets></p><p><offsets xml_i="48604" xml_f="48775" txt_i="36266" txt_f="36437">Improved gut barrier function is hypothesized to reduce metabolic endotoxemia, especially the concentration of highly inflammatory LPS, and reduce low-grade inflammation (</offsets><xref rid="bb0020" ref-type="bibr"><offsets xml_i="48810" xml_f="48831" txt_i="36437" txt_f="36458">Burcelin et al., 2009</offsets></xref><offsets xml_i="48838" xml_f="48936" txt_i="36458" txt_f="36556">). Our earlier studies have shown that B420 improves epithelial barrier function in cell culture (</offsets><xref rid="bb0170" ref-type="bibr"><offsets xml_i="48971" xml_f="48991" txt_i="36556" txt_f="36576">Putaala et al., 2008</offsets></xref><offsets xml_i="48998" xml_f="49040" txt_i="36576" txt_f="36618">) and reduces epithelial translocation of </offsets><italic><offsets xml_i="49048" xml_f="49055" txt_i="36618" txt_f="36625">E. coli</offsets></italic><offsets xml_i="49064" xml_f="49108" txt_i="36625" txt_f="36669"> as well as circulating LPS levels in mice (</offsets><xref rid="bb0005" ref-type="bibr"><offsets xml_i="49143" xml_f="49160" txt_i="36669" txt_f="36686">Amar et al., 2011</offsets></xref><offsets xml_i="49167" xml_f="49169" txt_i="36686" txt_f="36688">, </offsets><xref rid="bb0200" ref-type="bibr"><offsets xml_i="49204" xml_f="49224" txt_i="36688" txt_f="36708">Stenman et al., 2014</offsets></xref><offsets xml_i="49231" xml_f="49446" txt_i="36708" txt_f="36923">). We have also recently shown that LU + B420 modulates the intestinal immune system in mice and changes the microbial DNA signature in adipose tissue, which were associated with improvements in glucose metabolism (</offsets><xref rid="bb0040" ref-type="bibr"><offsets xml_i="49481" xml_f="49501" txt_i="36923" txt_f="36943">Garidou et al., 2015</offsets></xref><offsets xml_i="49508" xml_f="49510" txt_i="36943" txt_f="36945">).</offsets></p><p><offsets xml_i="49517" xml_f="50172" txt_i="36946" txt_f="37601">In this present study we saw a subtle increase in plasma LPS levels without activation of inflammatory responses. LPS levels were below or close to the detection limit both at baseline and at the end of intervention, questioning the clinical relevance of this LPS increase. However, this finding could point to a different manifestation of metabolic endotoxemia between mice and humans. The LAL methodology detects total LPS level in a sample and does not specify which bacterial species the LPS molecules originate from. It has been reported that the LPS levels detected with the LAL method may considerably differ from their cytokine-producing potency (</offsets><xref rid="bb0050" ref-type="bibr"><offsets xml_i="50207" xml_f="50228" txt_i="37601" txt_f="37622">Gutsmann et al., 2010</offsets></xref><offsets xml_i="50235" xml_f="50473" txt_i="37622" txt_f="37860">). Thus, although the level of total LPS was increased with LU + B420 treatment, its quality and inflammatory potency may have also been changed by the treatment. This hypothesis was supported by the tendency towards reduced hsCRP levels.</offsets></p><p><offsets xml_i="50480" xml_f="50932" txt_i="37861" txt_f="38313">We did not see treatment-associated reductions in blood glucose, HbA1c, insulin or HOMA-IR in the present study. Although we recruited overweight and obese participants, baseline laboratory values indicated that the participants had normal fasting glucose (average 5.18–5.24 mmol/l) and insulin (average 7.84–9.07 mU/l) levels, leaving very little room for improvement. Previously, we have shown improvement in glucose metabolism with both B420 alone (</offsets><xref rid="bb0200" ref-type="bibr"><offsets xml_i="50967" xml_f="50987" txt_i="38313" txt_f="38333">Stenman et al., 2014</offsets></xref><offsets xml_i="50994" xml_f="50996" txt_i="38333" txt_f="38335">, </offsets><xref rid="bb0210" ref-type="bibr"><offsets xml_i="51031" xml_f="51052" txt_i="38335" txt_f="38356">Stenman et al., 2015b</offsets></xref><offsets xml_i="51059" xml_f="51089" txt_i="38356" txt_f="38386">) and in combination with LU (</offsets><xref rid="bb0040" ref-type="bibr"><offsets xml_i="51124" xml_f="51144" txt_i="38386" txt_f="38406">Garidou et al., 2015</offsets></xref><offsets xml_i="51151" xml_f="51270" txt_i="38406" txt_f="38525">). The treatments should be tested in populations with impaired glucose metabolism or in patients with type 2 diabetes.</offsets></p><p><offsets xml_i="51277" xml_f="52236" txt_i="38526" txt_f="39485">This randomized, double-blind, placebo-controlled clinical intervention trial in overweight and obese adults presents preliminary clinical evidence that the probiotic B420 with or without Litesse Ultra polydextrose can reduce body fat mass, waist circumference, energy intake and body weight compared to placebo. Our findings are of special interest to populations who struggle to control their weight in a Western cultural environment. Additionally, B420 and LU seem to have synergistic effects in increasing lean body mass. LU alone had no effect on the parameters tested. Mechanistically, the reduction of body fat mass might be related to circulating zonulin, a potential marker of gut barrier function, and attenuated low-grade inflammation, which both support previous findings from experimental animals. Further clinical trials are warranted to confirm these effects in larger participant populations and to further elucidate the underlying mechanisms.</offsets></p></sec><sec id="s0115"><title><offsets xml_i="52269" xml_f="52284" txt_i="39487" txt_f="39502">Funding Sources</offsets></title><p><offsets xml_i="52295" xml_f="52569" txt_i="39503" txt_f="39773">This study was fully funded by DuPont Nutrition &amp; Health. DuPont, Smerud and the Principal Investigator were jointly responsible for drafting the study protocol and reports as well as interpretation of the data. The lead author of this manuscript was employed at DuPont.</offsets></p></sec><sec id="s0120"><title><offsets xml_i="52602" xml_f="52623" txt_i="39775" txt_f="39796">Conflicts of Interest</offsets></title><p><offsets xml_i="52634" xml_f="52957" txt_i="39797" txt_f="40116">This study was fully funded by DuPont Nutrition &amp; Health. Each of the authors or their respective organizations were financially compensated by DuPont for their contribution in the study. In addition, M.S. is a shareholder of Clinical Research Services Turku, and M.C. and R.B. are founders and shareholders of Vaiomer.</offsets></p></sec><sec id="s0125"><title><offsets xml_i="52990" xml_f="53010" txt_i="40118" txt_f="40138">Author Contributions</offsets></title><p><offsets xml_i="53021" xml_f="53498" txt_i="40139" txt_f="40612">Conceptualization, R.B., S.L.; Methodology, L.K.S., M.J.L., N.M., H.K.S., A.R., and S.L.; Formal Analysis, N.M.; Investigation, L.K.S., M.J.L., N.M., J.E.C., N.Y., M.T.S., M-L.L., J.L., D.A., and M.S.; Resources, M.C., M-L.L., J.L., D.A., M.S., and S.L.; Writing—Original Draft, L.K.S.; Writing—Review &amp; Editing, M.J.L., N.M., N.Y., M.T.S., R.B., H.K.S., M.S. and S.L.; Visualization, L.K.S. and N.M; Supervision, R.B., H.K.S, A.R., and S.L.; Project Administration, L.K.S.</offsets></p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Amar</surname><given-names>J.</given-names></name><name><surname>Chabo</surname><given-names>C.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Klopp</surname><given-names>P.</given-names></name><name><surname>Vachoux</surname><given-names>C.</given-names></name><name><surname>Bermudez-Humaran</surname><given-names>L.G.</given-names></name><name><surname>Smirnova</surname><given-names>N.</given-names></name><name><surname>Berge</surname><given-names>M.</given-names></name><name><surname>Sulpice</surname><given-names>T.</given-names></name><name><surname>Lahtinen</surname><given-names>S.</given-names></name><name><surname>Ouwehand</surname><given-names>A.</given-names></name><name><surname>Langella</surname><given-names>P.</given-names></name><name><surname>Rautonen</surname><given-names>N.</given-names></name><name><surname>Sansonetti</surname><given-names>P.J.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name></person-group><article-title>Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment</article-title><source>EMBO Mol. Med.</source><volume>3</volume><year>2011</year><fpage>559</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">21735552</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Brillon</surname><given-names>D.J.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Campbell</surname><given-names>R.G.</given-names></name><name><surname>Matthews</surname><given-names>D.E.</given-names></name></person-group><article-title>Effect of cortisol on energy expenditure and amino acid metabolism in humans</article-title><source>Am. J. Phys.</source><volume>268</volume><year>1995</year><fpage>E501</fpage><lpage>E513</lpage></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>P.</given-names></name><name><surname>Castagliuolo</surname><given-names>I.</given-names></name><name><surname>Di Leo</surname><given-names>V.</given-names></name><name><surname>Buda</surname><given-names>A.</given-names></name><name><surname>Pinzani</surname><given-names>M.</given-names></name><name><surname>Palu</surname><given-names>G.</given-names></name><name><surname>Martines</surname><given-names>D.</given-names></name></person-group><article-title>Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><volume>292</volume><year>2007</year><fpage>G518</fpage><lpage>G525</lpage><pub-id pub-id-type="pmid">17023554</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Luche</surname><given-names>E.</given-names></name><name><surname>Serino</surname><given-names>M.</given-names></name><name><surname>Amar</surname><given-names>J.</given-names></name></person-group><article-title>The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?</article-title><source>Front. Biosci. (Landmark Ed.)</source><volume>14</volume><year>2009</year><fpage>5107</fpage><lpage>5117</lpage><pub-id pub-id-type="pmid">19482607</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>P.D.</given-names></name><name><surname>Amar</surname><given-names>J.</given-names></name><name><surname>Iglesias</surname><given-names>M.A.</given-names></name><name><surname>Poggi</surname><given-names>M.</given-names></name><name><surname>Knauf</surname><given-names>C.</given-names></name><name><surname>Bastelica</surname><given-names>D.</given-names></name><name><surname>Neyrinck</surname><given-names>A.M.</given-names></name><name><surname>Fava</surname><given-names>F.</given-names></name><name><surname>Tuohy</surname><given-names>K.M.</given-names></name><name><surname>Chabo</surname><given-names>C.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Delmee</surname><given-names>E.</given-names></name><name><surname>Cousin</surname><given-names>B.</given-names></name><name><surname>Sulpice</surname><given-names>T.</given-names></name><name><surname>Chamontin</surname><given-names>B.</given-names></name><name><surname>Ferrieres</surname><given-names>J.</given-names></name><name><surname>Tanti</surname><given-names>J.F.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name><name><surname>Casteilla</surname><given-names>L.</given-names></name><name><surname>Delzenne</surname><given-names>N.M.</given-names></name><name><surname>Alessi</surname><given-names>M.C.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name></person-group><article-title>Metabolic endotoxemia initiates obesity and insulin resistance</article-title><source>Diabetes</source><volume>56</volume><year>2007</year><fpage>1761</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">17456850</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>El Asmar</surname><given-names>R.</given-names></name><name><surname>Panigrahi</surname><given-names>P.</given-names></name><name><surname>Bamford</surname><given-names>P.</given-names></name><name><surname>Berti</surname><given-names>I.</given-names></name><name><surname>Not</surname><given-names>T.</given-names></name><name><surname>Coppa</surname><given-names>G.V.</given-names></name><name><surname>Catassi</surname><given-names>C.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure</article-title><source>Gastroenterology</source><volume>123</volume><year>2002</year><fpage>1607</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">12404235</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>A.</given-names></name><name><surname>Not</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Uzzau</surname><given-names>S.</given-names></name><name><surname>Berti</surname><given-names>I.</given-names></name><name><surname>Tommasini</surname><given-names>A.</given-names></name><name><surname>Goldblum</surname><given-names>S.E.</given-names></name></person-group><article-title>Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease</article-title><source>Lancet</source><volume>355</volume><year>2000</year><fpage>1518</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">10801176</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Garidou</surname><given-names>L.</given-names></name><name><surname>Pomie</surname><given-names>C.</given-names></name><name><surname>Klopp</surname><given-names>P.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Charpentier</surname><given-names>J.</given-names></name><name><surname>Aloulou</surname><given-names>M.</given-names></name><name><surname>Giry</surname><given-names>A.</given-names></name><name><surname>Serino</surname><given-names>M.</given-names></name><name><surname>Stenman</surname><given-names>L.</given-names></name><name><surname>Lahtinen</surname><given-names>S.</given-names></name><name><surname>Dray</surname><given-names>C.</given-names></name><name><surname>Iacovoni</surname><given-names>J.S.</given-names></name><name><surname>Courtney</surname><given-names>M.</given-names></name><name><surname>Collet</surname><given-names>X.</given-names></name><name><surname>Amar</surname><given-names>J.</given-names></name><name><surname>Servant</surname><given-names>F.</given-names></name><name><surname>Lelouvier</surname><given-names>B.</given-names></name><name><surname>Valet</surname><given-names>P.</given-names></name><name><surname>Eberl</surname><given-names>G.</given-names></name><name><surname>Fazilleau</surname><given-names>N.</given-names></name><name><surname>Douin-Echinard</surname><given-names>V.</given-names></name><name><surname>Heymes</surname><given-names>C.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name></person-group><article-title>The gut microbiota regulates intestinal CD4 T cells expressing ROR-gamma-t and controls metabolic disease</article-title><source>Cell Metab.</source><volume>22</volume><year>2015</year><fpage>100</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">26154056</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>G.R.</given-names></name><name><surname>Roberfroid</surname><given-names>M.B.</given-names></name></person-group><article-title>Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics</article-title><source>J. Nutr.</source><volume>125</volume><year>1995</year><fpage>1401</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">7782892</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Gutsmann</surname><given-names>T.</given-names></name><name><surname>Howe</surname><given-names>J.</given-names></name><name><surname>Zahringer</surname><given-names>U.</given-names></name><name><surname>Garidel</surname><given-names>P.</given-names></name><name><surname>Schromm</surname><given-names>A.B.</given-names></name><name><surname>Koch</surname><given-names>M.H.</given-names></name><name><surname>Fujimoto</surname><given-names>Y.</given-names></name><name><surname>Fukase</surname><given-names>K.</given-names></name><name><surname>Moriyon</surname><given-names>I.</given-names></name><name><surname>Martinez-De-Tejada</surname><given-names>G.</given-names></name><name><surname>Brandenburg</surname><given-names>K.</given-names></name></person-group><article-title>Structural prerequisites for endotoxic activity in the Limulus test as compared to cytokine production in mononuclear cells</article-title><source>Innate Immun.</source><volume>16</volume><year>2010</year><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19567486</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>C.</given-names></name><name><surname>Guarner</surname><given-names>F.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name><name><surname>Merenstein</surname><given-names>D.J.</given-names></name><name><surname>Pot</surname><given-names>B.</given-names></name><name><surname>Morelli</surname><given-names>L.</given-names></name><name><surname>Canani</surname><given-names>R.B.</given-names></name><name><surname>Flint</surname><given-names>H.J.</given-names></name><name><surname>Salminen</surname><given-names>S.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name><name><surname>Sanders</surname><given-names>M.E.</given-names></name></person-group><article-title>Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><volume>11</volume><year>2014</year><fpage>506</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">24912386</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Ibarra</surname><given-names>A.</given-names></name><name><surname>Astbury</surname><given-names>N.M.</given-names></name><name><surname>Olli</surname><given-names>K.</given-names></name><name><surname>Alhoniemi</surname><given-names>E.</given-names></name><name><surname>Tiihonen</surname><given-names>K.</given-names></name></person-group><article-title>Effects of polydextrose on different levels of energy intake. A systematic review and meta-analysis</article-title><source>Appetite</source><volume>87</volume><year>2015</year><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">25510531</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Jie</surname><given-names>Z.</given-names></name><name><surname>Bang-Yao</surname><given-names>L.</given-names></name><name><surname>Ming-Jie</surname><given-names>X.</given-names></name><name><surname>Hai-Wei</surname><given-names>L.</given-names></name><name><surname>Zu-Kang</surname><given-names>Z.</given-names></name><name><surname>Ting-Song</surname><given-names>W.</given-names></name><name><surname>Craig</surname><given-names>S.A.</given-names></name></person-group><article-title>Studies on the effects of polydextrose intake on physiologic functions in Chinese people</article-title><source>Am. J. Clin. Nutr.</source><volume>72</volume><year>2000</year><fpage>1503</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">11101478</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Kadooka</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Imaizumi</surname><given-names>K.</given-names></name><name><surname>Ogawa</surname><given-names>A.</given-names></name><name><surname>Ikuyama</surname><given-names>K.</given-names></name><name><surname>Akai</surname><given-names>Y.</given-names></name><name><surname>Okano</surname><given-names>M.</given-names></name><name><surname>Kagoshima</surname><given-names>M.</given-names></name><name><surname>Tsuchida</surname><given-names>T.</given-names></name></person-group><article-title>Regulation of abdominal adiposity by probiotics (<italic>Lactobacillus gasseri</italic> SBT2055) in adults with obese tendencies in a randomized controlled trial</article-title><source>Eur. J. Clin. Nutr.</source><volume>64</volume><year>2010</year><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">20216555</pub-id></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Kadooka</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Ogawa</surname><given-names>A.</given-names></name><name><surname>Miyoshi</surname><given-names>M.</given-names></name><name><surname>Uenishi</surname><given-names>H.</given-names></name><name><surname>Ogawa</surname><given-names>H.</given-names></name><name><surname>Ikuyama</surname><given-names>K.</given-names></name><name><surname>Kagoshima</surname><given-names>M.</given-names></name><name><surname>Tsuchida</surname><given-names>T.</given-names></name></person-group><article-title>Effect of <italic>Lactobacillus gasseri</italic> SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial</article-title><source>Br. J. Nutr.</source><volume>110</volume><year>2013</year><fpage>1696</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">23614897</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Kallio</surname><given-names>K.A.</given-names></name><name><surname>Hatonen</surname><given-names>K.A.</given-names></name><name><surname>Lehto</surname><given-names>M.</given-names></name><name><surname>Salomaa</surname><given-names>V.</given-names></name><name><surname>Mannisto</surname><given-names>S.</given-names></name><name><surname>Pussinen</surname><given-names>P.J.</given-names></name></person-group><article-title>Endotoxemia, nutrition, and cardiometabolic disorders</article-title><source>Acta Diabetol.</source><volume>52</volume><year>2015</year><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">25326898</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>A.</given-names></name><name><surname>Friedrich</surname><given-names>U.</given-names></name><name><surname>Vogelsang</surname><given-names>H.</given-names></name><name><surname>Jahreis</surname><given-names>G.</given-names></name></person-group><article-title><italic>Lactobacillus acidophilus</italic> 74-2 and <italic>Bifidobacterium animalis</italic> subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults</article-title><source>Eur. J. Clin. Nutr.</source><volume>62</volume><year>2008</year><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">17440520</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Kok</surname><given-names>R.G.</given-names></name><name><surname>De Waal</surname><given-names>A.</given-names></name><name><surname>Schut</surname><given-names>F.</given-names></name><name><surname>Welling</surname><given-names>G.W.</given-names></name><name><surname>Weenk</surname><given-names>G.</given-names></name><name><surname>Hellingwerf</surname><given-names>K.J.</given-names></name></person-group><article-title>Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces</article-title><source>Appl. Environ. Microbiol.</source><volume>62</volume><year>1996</year><fpage>3668</fpage><lpage>3672</lpage><pub-id pub-id-type="pmid">8837422</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Kujala</surname><given-names>U.M.</given-names></name><name><surname>Kaprio</surname><given-names>J.</given-names></name><name><surname>Sarna</surname><given-names>S.</given-names></name><name><surname>Koskenvuo</surname><given-names>M.</given-names></name></person-group><article-title>Relationship of leisure-time physical activity and mortality: the Finnish twin cohort</article-title><source>JAMA</source><volume>279</volume><year>1998</year><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">9466636</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Leber</surname><given-names>B.</given-names></name><name><surname>Tripolt</surname><given-names>N.J.</given-names></name><name><surname>Blattl</surname><given-names>D.</given-names></name><name><surname>Eder</surname><given-names>M.</given-names></name><name><surname>Wascher</surname><given-names>T.C.</given-names></name><name><surname>Pieber</surname><given-names>T.R.</given-names></name><name><surname>Stauber</surname><given-names>R.</given-names></name><name><surname>Sourij</surname><given-names>H.</given-names></name><name><surname>Oettl</surname><given-names>K.</given-names></name><name><surname>Stadlbauer</surname><given-names>V.</given-names></name></person-group><article-title>The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study</article-title><source>Eur. J. Clin. Nutr.</source><volume>66</volume><year>2012</year><fpage>1110</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">22872030</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>R.E.</given-names></name><name><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name><surname>Klein</surname><given-names>S.</given-names></name><name><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>Microbial ecology: human gut microbes associated with obesity</article-title><source>Nature</source><volume>444</volume><year>2006</year><fpage>1022</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">17183309</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Guerin-Deremaux</surname><given-names>L.</given-names></name><name><surname>Pochat</surname><given-names>M.</given-names></name><name><surname>Wils</surname><given-names>D.</given-names></name><name><surname>Reifer</surname><given-names>C.</given-names></name><name><surname>Miller</surname><given-names>L.E.</given-names></name></person-group><article-title>NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study</article-title><source>Appl. Physiol. Nutr. Metab.</source><volume>35</volume><year>2010</year><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">21164548</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.H.</given-names></name><name><surname>Huang</surname><given-names>M.J.</given-names></name><name><surname>Zhang</surname><given-names>X.W.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>N.Q.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Lan</surname><given-names>P.</given-names></name><name><surname>Peng</surname><given-names>J.S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>H.L.</given-names></name><name><surname>Wang</surname><given-names>J.P.</given-names></name></person-group><article-title>The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial</article-title><source>Am. J. Clin. Nutr.</source><volume>97</volume><year>2013</year><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">23235200</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Loman</surname><given-names>T.</given-names></name><name><surname>Lallukka</surname><given-names>T.</given-names></name><name><surname>Laaksonen</surname><given-names>M.</given-names></name><name><surname>Rahkonen</surname><given-names>O.</given-names></name><name><surname>Lahelma</surname><given-names>E.</given-names></name></person-group><article-title>Multiple socioeconomic determinants of weight gain: the Helsinki health study</article-title><source>BMC Public Health</source><volume>13</volume><year>2013</year><fpage>259</fpage><pub-id pub-id-type="pmid">23517457</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Minami</surname><given-names>J.</given-names></name><name><surname>Kondo</surname><given-names>S.</given-names></name><name><surname>Yanagisawa</surname><given-names>N.</given-names></name><name><surname>Odamaki</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>J.Z.</given-names></name><name><surname>Abe</surname><given-names>F.</given-names></name><name><surname>Nakajima</surname><given-names>S.</given-names></name><name><surname>Hamamoto</surname><given-names>Y.</given-names></name><name><surname>Saitoh</surname><given-names>S.</given-names></name><name><surname>Shimoda</surname><given-names>T.</given-names></name></person-group><article-title>Oral administration of <italic>Bifidobacterium breve</italic> B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial</article-title><source>J. Nutr. Sci.</source><volume>4</volume><year>2015</year><object-id pub-id-type="publisher-id">e17</object-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Moreno-Navarrete</surname><given-names>J.M.</given-names></name><name><surname>Sabater</surname><given-names>M.</given-names></name><name><surname>Ortega</surname><given-names>F.</given-names></name><name><surname>Ricart</surname><given-names>W.</given-names></name><name><surname>Fernandez-Real</surname><given-names>J.M.</given-names></name></person-group><article-title>Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e37160</object-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>O'neil</surname><given-names>P.M.</given-names></name><name><surname>Smith</surname><given-names>S.R.</given-names></name><name><surname>Weissman</surname><given-names>N.J.</given-names></name><name><surname>Fidler</surname><given-names>M.C.</given-names></name><name><surname>Sanchez</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Raether</surname><given-names>B.</given-names></name><name><surname>Anderson</surname><given-names>C.M.</given-names></name><name><surname>Shanahan</surname><given-names>W.R.</given-names></name></person-group><article-title>Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study</article-title><source>Obesity (Silver Spring)</source><volume>20</volume><year>2012</year><fpage>1426</fpage><lpage>1436</lpage><pub-id pub-id-type="pmid">22421927</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Osterberg</surname><given-names>K.L.</given-names></name><name><surname>Boutagy</surname><given-names>N.E.</given-names></name><name><surname>Mcmillan</surname><given-names>R.P.</given-names></name><name><surname>Stevens</surname><given-names>J.R.</given-names></name><name><surname>Frisard</surname><given-names>M.I.</given-names></name><name><surname>Kavanaugh</surname><given-names>J.W.</given-names></name><name><surname>Davy</surname><given-names>B.M.</given-names></name><name><surname>Davy</surname><given-names>K.P.</given-names></name><name><surname>Hulver</surname><given-names>M.W.</given-names></name></person-group><article-title>Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults</article-title><source>Obesity (Silver Spring)</source><volume>23</volume><year>2015</year><fpage>2364</fpage><lpage>2370</lpage><pub-id pub-id-type="pmid">26466123</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Pacifico</surname><given-names>L.</given-names></name><name><surname>Bonci</surname><given-names>E.</given-names></name><name><surname>Marandola</surname><given-names>L.</given-names></name><name><surname>Romaggioli</surname><given-names>S.</given-names></name><name><surname>Bascetta</surname><given-names>S.</given-names></name><name><surname>Chiesa</surname><given-names>C.</given-names></name></person-group><article-title>Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease</article-title><source>World J. Gastroenterol.</source><volume>20</volume><year>2014</year><fpage>17107</fpage><lpage>17114</lpage><pub-id pub-id-type="pmid">25493023</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Parnell</surname><given-names>J.A.</given-names></name><name><surname>Reimer</surname><given-names>R.A.</given-names></name></person-group><article-title>Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults</article-title><source>Am. J. Clin. Nutr.</source><volume>89</volume><year>2009</year><fpage>1751</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">19386741</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Pendyala</surname><given-names>S.</given-names></name><name><surname>Walker</surname><given-names>J.M.</given-names></name><name><surname>Holt</surname><given-names>P.R.</given-names></name></person-group><article-title>A high-fat diet is associated with endotoxemia that originates from the gut</article-title><source>Gastroenterology</source><volume>142</volume><year>2012</year><comment>(1100-1.e2)</comment></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Pi-Sunyer</surname><given-names>X.</given-names></name><name><surname>Astrup</surname><given-names>A.</given-names></name><name><surname>Fujioka</surname><given-names>K.</given-names></name><name><surname>Greenway</surname><given-names>F.</given-names></name><name><surname>Halpern</surname><given-names>A.</given-names></name><name><surname>KREMPF</surname><given-names>M.</given-names></name><name><surname>Lau</surname><given-names>D.C.</given-names></name><name><surname>Le Roux</surname><given-names>C.W.</given-names></name><name><surname>Violante Ortiz</surname><given-names>R.</given-names></name><name><surname>Jensen</surname><given-names>C.B.</given-names></name><name><surname>Wilding</surname><given-names>J.P.</given-names></name><name><surname>Obesity, S. &amp; Prediabetes, NNSG</surname></name></person-group><article-title>A randomized, controlled trial of 3.0 mg of Liraglutide in weight management</article-title><source>N. Engl. J. Med.</source><volume>373</volume><year>2015</year><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">26132939</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Probert</surname><given-names>H.M.</given-names></name><name><surname>Apajalahti</surname><given-names>J.H.</given-names></name><name><surname>Rautonen</surname><given-names>N.</given-names></name><name><surname>Stowell</surname><given-names>J.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name></person-group><article-title>Polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system</article-title><source>Appl. Environ. Microbiol.</source><volume>70</volume><year>2004</year><fpage>4505</fpage><lpage>4511</lpage><pub-id pub-id-type="pmid">15294779</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Putaala</surname><given-names>H.</given-names></name><name><surname>Salusjarvi</surname><given-names>T.</given-names></name><name><surname>Nordstrom</surname><given-names>M.</given-names></name><name><surname>Saarinen</surname><given-names>M.</given-names></name><name><surname>Ouwehand</surname><given-names>A.C.</given-names></name><name><surname>Bech Hansen</surname><given-names>E.</given-names></name><name><surname>Rautonen</surname><given-names>N.</given-names></name></person-group><article-title>Effect of four probiotic strains and <italic>Escherichia coli</italic> O157:H7 on tight junction integrity and cyclooxygenase expression</article-title><source>Res. Microbiol.</source><volume>159</volume><year>2008</year><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">18783733</pub-id></element-citation></ref><ref id="bb0175"><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Roessler</surname><given-names>A.</given-names></name><name><surname>Friedrich</surname><given-names>U.</given-names></name><name><surname>Vogelsang</surname><given-names>H.</given-names></name><name><surname>Bauer</surname><given-names>A.</given-names></name><name><surname>Kaatz</surname><given-names>M.</given-names></name><name><surname>Hipler</surname><given-names>U.C.</given-names></name><name><surname>Schmidt</surname><given-names>I.</given-names></name><name><surname>Jahreis</surname><given-names>G.</given-names></name></person-group><article-title>The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention</article-title><source>Clin. Exp. Allergy</source><volume>38</volume><year>2008</year><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">18028460</pub-id></element-citation></ref><ref id="bb0180"><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>F.</given-names></name><name><surname>Linsalata</surname><given-names>M.</given-names></name><name><surname>Clemente</surname><given-names>C.</given-names></name><name><surname>Chiloiro</surname><given-names>M.</given-names></name><name><surname>Orlando</surname><given-names>A.</given-names></name><name><surname>Marconi</surname><given-names>E.</given-names></name><name><surname>Chimienti</surname><given-names>G.</given-names></name><name><surname>Riezzo</surname><given-names>G.</given-names></name></person-group><article-title>Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers</article-title><source>Nutr. Res.</source><volume>32</volume><year>2012</year><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">23244539</pub-id></element-citation></ref><ref id="bb0185"><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>M.</given-names></name><name><surname>Darimont</surname><given-names>C.</given-names></name><name><surname>Drapeau</surname><given-names>V.</given-names></name><name><surname>Emady-Azar</surname><given-names>S.</given-names></name><name><surname>Lepage</surname><given-names>M.</given-names></name><name><surname>Rezzonico</surname><given-names>E.</given-names></name><name><surname>Ngom-Bru</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>B.</given-names></name><name><surname>Philippe</surname><given-names>L.</given-names></name><name><surname>Ammon-Zuffrey</surname><given-names>C.</given-names></name><name><surname>Leone</surname><given-names>P.</given-names></name><name><surname>Chevrier</surname><given-names>G.</given-names></name><name><surname>St-Amand</surname><given-names>E.</given-names></name><name><surname>Marette</surname><given-names>A.</given-names></name><name><surname>Dore</surname><given-names>J.</given-names></name><name><surname>Tremblay</surname><given-names>A.</given-names></name></person-group><article-title>Effect of <italic>Lactobacillus rhamnosus</italic> CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women</article-title><source>Br. J. Nutr.</source><volume>111</volume><year>2014</year><fpage>1507</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">24299712</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Sapone</surname><given-names>A.</given-names></name><name><surname>De Magistris</surname><given-names>L.</given-names></name><name><surname>Pietzak</surname><given-names>M.</given-names></name><name><surname>Clemente</surname><given-names>M.G.</given-names></name><name><surname>Tripathi</surname><given-names>A.</given-names></name><name><surname>Cucca</surname><given-names>F.</given-names></name><name><surname>Lampis</surname><given-names>R.</given-names></name><name><surname>Kryszak</surname><given-names>D.</given-names></name><name><surname>Carteni</surname><given-names>M.</given-names></name><name><surname>Generoso</surname><given-names>M.</given-names></name><name><surname>Iafusco</surname><given-names>D.</given-names></name><name><surname>Prisco</surname><given-names>F.</given-names></name><name><surname>Laghi</surname><given-names>F.</given-names></name><name><surname>Riegler</surname><given-names>G.</given-names></name><name><surname>Carratu</surname><given-names>R.</given-names></name><name><surname>Counts</surname><given-names>D.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives</article-title><source>Diabetes</source><volume>55</volume><year>2006</year><fpage>1443</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">16644703</pub-id></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Stenman</surname><given-names>L.K.</given-names></name><name><surname>Holma</surname><given-names>R.</given-names></name><name><surname>Korpela</surname><given-names>R.</given-names></name></person-group><article-title>High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids</article-title><source>World J. Gastroenterol.</source><volume>18</volume><year>2012</year><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">22408351</pub-id></element-citation></ref><ref id="bb0200"><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Stenman</surname><given-names>L.K.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Garret</surname><given-names>C.</given-names></name><name><surname>Klopp</surname><given-names>P.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Lahtinen</surname><given-names>S.</given-names></name></person-group><article-title>Potential probiotic <italic>Bifidobacterium animalis</italic> ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice</article-title><source>Benefic. Microbes</source><volume>5</volume><year>2014</year><fpage>437</fpage><lpage>445</lpage></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Stenman</surname><given-names>L.K.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Lahtinen</surname><given-names>S.</given-names></name></person-group><article-title>Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans—towards treatment with probiotics</article-title><source>Benefic. Microbes</source><year>2015</year><fpage>1</fpage><lpage>12</lpage><comment>(E-pub ahead of print)</comment></element-citation></ref><ref id="bb0210"><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Stenman</surname><given-names>L.K.</given-names></name><name><surname>Waget</surname><given-names>A.</given-names></name><name><surname>Garret</surname><given-names>C.</given-names></name><name><surname>Briand</surname><given-names>F.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Sulpice</surname><given-names>T.</given-names></name><name><surname>Lahtinen</surname><given-names>S.</given-names></name></person-group><article-title>Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice</article-title><source>Diabetol. Metab. Syndr.</source><volume>7</volume><year>2015</year><fpage>75</fpage><pub-id pub-id-type="pmid">26366205</pub-id></element-citation></ref><ref id="bb0215"><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>T.F.</given-names></name><name><surname>Souza</surname><given-names>N.C.</given-names></name><name><surname>Chiarello</surname><given-names>P.G.</given-names></name><name><surname>Franceschini</surname><given-names>S.C.</given-names></name><name><surname>Bressan</surname><given-names>J.</given-names></name><name><surname>Ferreira</surname><given-names>C.L.</given-names></name><name><surname>Peluzio Mdo</surname><given-names>C.</given-names></name></person-group><article-title>Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors</article-title><source>Clin. Nutr.</source><volume>31</volume><year>2012</year><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">22444236</pub-id></element-citation></ref><ref id="bb0220"><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Torgerson</surname><given-names>J.S.</given-names></name><name><surname>Hauptman</surname><given-names>J.</given-names></name><name><surname>Boldrin</surname><given-names>M.N.</given-names></name><name><surname>Sjostrom</surname><given-names>L.</given-names></name></person-group><article-title>XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients</article-title><source>Diabetes Care</source><volume>27</volume><year>2004</year><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">14693982</pub-id></element-citation></ref><ref id="bb0225"><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>J.</given-names></name><name><surname>Lindstrom</surname><given-names>J.</given-names></name><name><surname>Eriksson</surname><given-names>J.G.</given-names></name><name><surname>Valle</surname><given-names>T.T.</given-names></name><name><surname>Hamalainen</surname><given-names>H.</given-names></name><name><surname>Ilanne-Parikka</surname><given-names>P.</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname><given-names>S.</given-names></name><name><surname>Laakso</surname><given-names>M.</given-names></name><name><surname>Louheranta</surname><given-names>A.</given-names></name><name><surname>Rastas</surname><given-names>M.</given-names></name><name><surname>Salminen</surname><given-names>V.</given-names></name><name><surname>Uusitupa</surname><given-names>M.</given-names></name><name><surname>Finnish Diabetes Prevention Study, G</surname></name></person-group><article-title>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</article-title><source>N. Engl. J. Med.</source><volume>344</volume><year>2001</year><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">11333990</pub-id></element-citation></ref><ref id="bb0230"><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name><surname>Ley</surname><given-names>R.E.</given-names></name><name><surname>Mahowald</surname><given-names>M.A.</given-names></name><name><surname>Magrini</surname><given-names>V.</given-names></name><name><surname>Mardis</surname><given-names>E.R.</given-names></name><name><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>An obesity-associated gut microbiome with increased capacity for energy harvest</article-title><source>Nature</source><volume>444</volume><year>2006</year><fpage>1027</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">17183312</pub-id></element-citation></ref><ref id="bb0235"><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Uzzau</surname><given-names>S.</given-names></name><name><surname>Goldblum</surname><given-names>S.E.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group><article-title>Human zonulin, a potential modulator of intestinal tight junctions</article-title><source>J. Cell Sci.</source><volume>113</volume><issue>Pt 24</issue><year>2000</year><fpage>4435</fpage><lpage>4440</lpage><pub-id pub-id-type="pmid">11082037</pub-id></element-citation></ref><ref id="bb0240"><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Yue</surname><given-names>F.</given-names></name><name><surname>Russell</surname><given-names>R.D.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name></person-group><article-title>Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients</article-title><source>Diabetes Res. Clin. Pract.</source><volume>106</volume><year>2014</year><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">25238913</pub-id></element-citation></ref><ref id="bb0245"><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Zunszain</surname><given-names>P.A.</given-names></name><name><surname>Anacker</surname><given-names>C.</given-names></name><name><surname>Cattaneo</surname><given-names>A.</given-names></name><name><surname>Carvalho</surname><given-names>L.A.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name></person-group><article-title>Glucocorticoids, cytokines and brain abnormalities in depression</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><volume>35</volume><year>2011</year><fpage>722</fpage><lpage>729</lpage></element-citation></ref></ref-list><sec id="s0130" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.pdf"><alt-text>Image 1</alt-text></media></supplementary-material></p></sec><ack id="ac0005"><title>Acknowledgements</title><p>We wish to extend our gratitude to the study participants, investigators, monitors and study nurses who enabled this study. We are especially thankful to Yvonne Peltonen for her firm study management. Also, we are thankful to Angela Paulsen and Tad Stewart from DuPont Nutrition &amp; Health for the production and quality control of the study products, as well as to all who participated in sample analyses: Jaana Larsson-Leskelä, Henri Ahokoski, Kirsi Stenström and Sari Pohjola. We are also very grateful to Tiina Roine and Auli Väänänen for food diary data extraction.</p></ack><fn-group><fn id="d32e3672"><label>☆</label><p id="np0030">Conflict of interest statement: LKS, MJL, NY, MTS and SL are employees of DuPont Nutrition &amp; Health.</p></fn><fn id="d32e3677"><label>☆☆</label><p id="np0035">The research was funded by <funding-source id="gts0005">DuPont Nutrition &amp; Health</funding-source>.</p></fn><fn id="s0135" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ebiom.2016.10.036" id="ir0025">http://dx.doi.org/10.1016/j.ebiom.2016.10.036</ext-link>.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>Participant flow. Before unblinding the study, participants were divided into an Intention-to-Treat (ITT) population and a Per Protocol (PP) population according to adherence to the study protocol.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig><fig id="f0010"><label>Fig. 2</label><caption><p>Weight management outcomes. Change in total body fat mass from baseline to end of study (6 months of intervention) in the Intention-to-Treat (a) and Per Protocol (PP) (b) populations. Evolution of body fat mass in the PP population during intervention and at follow-up (c). Changes in trunk fat mass (d), android fat mass (e), lean body mass (f), body weight (g), waist circumference (h) and hip circumference (i) from baseline to end of study in the PP population. Body composition in panels a-f was measured with dual-energy X-ray absorptiometry. Results are expressed as mean ± 95% CI. Results were analyzed with ANCOVA and Dunnett's pairwise comparisons corrected for multiple testing. In the ITT population, the last observation was carried forward for the statistical analysis of participants who withdrew from the study. Solid line shows baseline; dotted line shows the level of the Placebo group. N of participants included in the statistical analysis in the Intention-to-Treat population: Placebo <italic>n</italic> = 53, LU <italic>n</italic> = 51, B420 <italic>n</italic> = 47, LU + B420 <italic>n</italic> = 48. N for the PP population: Placebo <italic>n</italic> = 35–36, LU <italic>n</italic> = 35–36, B420 <italic>n</italic> = 24–25, LU + B420 <italic>n</italic> = 37. Overall ANCOVA as follows: a) <italic>P</italic> = 0.46, b) <italic>P</italic> = 0.095, d) <italic>P</italic> = 0.036, e) <italic>P</italic> = 0.23, f) <italic>P</italic> = 0.30, g) <italic>P</italic> = 0.13, h) <italic>P</italic> = 0.10, i) <italic>P</italic> = 0.31.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig><fig id="f0015"><label>Fig. 3</label><caption><p>Correlation between serum zonulin, serum hsCRP and trunk fat mass. Evolution of zonulin (a) and hsCRP (c), and correlations between zonulin (b) and hsCRP (d) with trunk fat mass as changes from baseline to end-of-intervention (6 months) in the Per Protocol population. Panels a) and c) display changes from baseline as mean ± 95% confidence intervals at each time point. Placebo <italic>n</italic> = 35–36, LU <italic>n</italic> = 35–36, B420 <italic>n</italic> = 24–25, LU + B420 <italic>n</italic> = 36–37.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Baseline demographics of the Intention-to-Treat and Per Protocol populations.</p></caption><alt-text id="al0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th>Placebo</th><th>LU</th><th>B420</th><th>LU + B420</th><th>Total</th></tr></thead><tbody><tr><td>Intention-to-Treat</td><td><italic>n</italic></td><td>56</td><td>53</td><td>48</td><td>52</td><td>209</td></tr><tr><td>Gender</td><td>n, Male/Female</td><td>12/44</td><td>12/41</td><td>9/39</td><td>9/43</td><td>42/167</td></tr><tr><td>Ethnicity</td><td>n, Caucasian/Other</td><td>55/1</td><td>52/1</td><td>48/0</td><td>51/1</td><td>206/3</td></tr><tr><td>Age, years</td><td>mean ± SD</td><td>49.9 ± 8.5</td><td>48.8 ± 10.5</td><td>50.6 ± 10.6</td><td>47.0 ± 11.1</td><td>49.1 ± 10.2</td></tr><tr><td>Weight, kg</td><td>mean ± SD</td><td>88.5 ± 12.2</td><td>89.4 ± 9.1</td><td>88.7 ± 9.3</td><td>87.8 ± 11.0</td><td>88.6 ± 10.4</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>mean ± SD</td><td>31.2 ± 2.2</td><td>31.2 ± 1.6</td><td>31.5 ± 2.2</td><td>31.3 ± 2.0</td><td>31.3 ± 2.0</td></tr><tr><td>Waist circumference, cm</td><td>mean ± SD</td><td>103.0 ± 8.4</td><td>103.4 ± 6.1</td><td>102.6 ± 6.9</td><td>102.5 ± 6.9</td><td>102.9 ± 7.1</td></tr><tr><td>Blood glucose, mmol/l</td><td>mean ± SD</td><td>5.24 ± 0.50</td><td>5.20 ± 0.62</td><td>5.18 ± 0.43</td><td>5.19 ± 0.42</td><td>5.20 ± 0.50</td></tr><tr><td>Total Cholesterol, mmol/l</td><td>mean ± SD</td><td>5.23 ± 0.87</td><td>5.22 ± 1.00</td><td>5.26 ± 1.08</td><td>5.50 ± 0.96</td><td>5.30 ± 0.97</td></tr><tr><td>LDL Cholesterol, mmol/l</td><td>mean ± SD</td><td>3.10 ± 0.77</td><td>3.08 ± 0.82</td><td>3.25 ± 0.91</td><td>3.38 ± 0.89</td><td>3.20 ± 0.85</td></tr><tr><td>Triglycerides, mmol/l</td><td>mean ± SD</td><td>1.22 ± 0.61</td><td>1.27 ± 0.53</td><td>1.27 ± 0.56</td><td>1.29 ± 0.61</td><td>1.26 ± 0.58</td></tr><tr><td>Per-Protocol</td><td><italic>n</italic></td><td>36</td><td>36</td><td>25</td><td>37</td><td>134</td></tr><tr><td>Gender</td><td>n, Male/Female</td><td>10/26</td><td>8/28</td><td>7/18</td><td>6/31</td><td>31/103</td></tr><tr><td>Ethnicity</td><td>n, Caucasian/Other</td><td>36/0</td><td>35/1</td><td>25/0</td><td>37/0</td><td>133/1</td></tr><tr><td>Age, years</td><td>mean ± SD</td><td>48.3 ± 8.6</td><td>48.6 ± 10.9</td><td>49.1 ± 11.9</td><td>47.1 ± 10.9</td><td>48.2 ± 10.4</td></tr><tr><td>Weight, kg</td><td>mean ± SD</td><td>88.7 ± 12.5</td><td>89.7 ± 9.4</td><td>88.9 ± 10.3</td><td>87.7 ± 11.3</td><td>88.7 ± 10.9</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>mean ± SD</td><td>31.0 ± 2.2</td><td>31.2 ± 1.6</td><td>30.9 ± 1.9</td><td>31.2 ± 2.0</td><td>31.1 ± 1.9</td></tr><tr><td>Waist circumference, cm</td><td>mean ± SD</td><td>102.1 ± 7.5</td><td>103.3 ± 6.6</td><td>103.3 ± 7.5</td><td>102.1 ± 7.3</td><td>102.7 ± 7.2</td></tr><tr><td>Blood glucose, mmol/l</td><td>mean ± SD</td><td>5.21 ± 0.54</td><td>5.18 ± 0.68</td><td>5.16 ± 0.35</td><td>5.22 ± 0.42</td><td>5.20 ± 0.52</td></tr><tr><td>Total Cholesterol, mmol/l</td><td>mean ± SD</td><td>5.16 ± 0.86</td><td>5.24 ± 1.01</td><td>5.14 ± 0.86</td><td>5.58 ± 0.90</td><td>5.29 ± 0.92</td></tr><tr><td>LDL Cholesterol, mmol/l</td><td>mean ± SD</td><td>3.05 ± 0.75</td><td>3.12 ± 0.73</td><td>3.12 ± 0.66</td><td>3.39 ± 0.84</td><td>3.17 ± 0.76</td></tr><tr><td>Triglycerides, mmol/l</td><td>mean ± SD</td><td>1.20 ± 0.67</td><td>1.25 ± 0.54</td><td>1.33 ± 0.58</td><td>1.36 ± 0.66</td><td>1.28 ± 0.62</td></tr></tbody></table></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Changes in food intake during the study, as assessed with 5-day food diaries (Per Protocol population).</p></caption><alt-text id="al0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><hr></hr></th><th rowspan="2"><hr></hr></th><th colspan="4">Energy intake (kcal/day)<hr></hr></th><th colspan="4">Fat intake (g/day)<hr></hr></th><th colspan="4">Relative fat intake (% kcal)<hr></hr></th><th colspan="4">Fiber intake (g/day)<hr></hr></th></tr><tr><th colspan="2"><italic>Absolute</italic><hr></hr></th><th colspan="2"><italic>Change from baseline</italic><hr></hr></th><th colspan="2"><italic>Absolute</italic><hr></hr></th><th colspan="2"><italic>Change from baseline</italic><hr></hr></th><th colspan="2"><italic>Absolute</italic><hr></hr></th><th colspan="2"><italic>Change from baseline</italic><hr></hr></th><th colspan="2"><italic>Absolute</italic><hr></hr></th><th colspan="2"><italic>Change from baseline</italic><hr></hr></th></tr><tr><th><italic>Overall P</italic></th><th></th><th colspan="2"></th><th colspan="2"><italic>P = 0.005</italic></th><th colspan="2"></th><th colspan="2"><italic>P = 0.008</italic></th><th colspan="2"></th><th colspan="2"><italic>P = 0.058</italic></th><th colspan="2"></th><th colspan="2"><italic>P = 0.055</italic></th></tr><tr><th><italic>Group</italic></th><th><italic>Visit</italic></th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th><th>n</th><th>Mean ± SD</th></tr></thead><tbody><tr><td rowspan="3">Placebo<xref rid="tf0010" ref-type="table-fn">a</xref></td><td><italic>Baseline</italic></td><td>33</td><td>2240 ± 510</td><td>0</td><td>–</td><td>33</td><td>96 ± 32</td><td>0</td><td>–</td><td>33</td><td>38 ± 7</td><td>0</td><td>–</td><td>33</td><td>21 ± 6.6</td><td>0</td><td>–</td></tr><tr><td><italic>Month 2</italic></td><td>34</td><td>2270 ± 570</td><td>31</td><td>57 ± 500</td><td>34</td><td>90 ± 32</td><td>31</td><td>− 4.9 ± 32</td><td>34</td><td>35 ± 7</td><td>31</td><td>− 2.7 ± 6</td><td>34</td><td>20 ± 7.3</td><td>31</td><td>− 1.3 ± 7</td></tr><tr><td><italic>Month 6</italic></td><td>36</td><td>2180 ± 460</td><td>33</td><td>− 23 ± 600</td><td>36</td><td>92 ± 31</td><td>33</td><td>− 2.2 ± 43</td><td>36</td><td>37 ± 7</td><td>33</td><td>− 0.6 ± 8</td><td>36</td><td>20 ± 5.6</td><td>33</td><td>− 1.2 ± 6</td></tr><tr><td rowspan="3">LU</td><td><italic>Baseline</italic></td><td>33</td><td>2210 ± 650</td><td>0</td><td>–</td><td>33</td><td>92 ± 29</td><td>0</td><td>–</td><td>33</td><td>38 ± 5</td><td>0</td><td>–</td><td>33</td><td>22 ± 7.9</td><td>0</td><td>–</td></tr><tr><td><italic>Month 2</italic></td><td>35</td><td>2170 ± 640</td><td>33</td><td>− 15 ± 430</td><td>35</td><td>93 ± 31</td><td>33</td><td>2.2 ± 23</td><td>35</td><td>39 ± 5</td><td>33</td><td>0.9 ± 6</td><td>35</td><td>20 ± 9.2</td><td>33</td><td>− 1.5 ± 7</td></tr><tr><td><italic>Month 6</italic></td><td>34</td><td>2000 ± 520</td><td>33</td><td>− 200 ± 510</td><td>34</td><td>80 ± 27</td><td>33</td><td>− 12 ± 24</td><td>34</td><td>35 ± 4</td><td>33</td><td>− 2.0 ± 6</td><td>34</td><td>21 ± 9.3</td><td>33</td><td>− 1.1 ± 6</td></tr><tr><td rowspan="3">B420</td><td><italic>Baseline</italic></td><td>24</td><td>2200 ± 380</td><td>0</td><td>–</td><td>24</td><td>94 ± 22</td><td>0</td><td>–</td><td>24</td><td>38 ± 5</td><td>0</td><td>–</td><td>24</td><td>24 ± 6.6</td><td>0</td><td>–</td></tr><tr><td><italic>Month 2</italic></td><td>22</td><td>2130 ± 380</td><td>22</td><td>− 120 ± 250</td><td>22</td><td>87 ± 26</td><td>22</td><td>− 9.7 ± 18</td><td>22</td><td>36 ± 7</td><td>22</td><td>− 2.4 ± 6</td><td>22</td><td>19 ± 5.7</td><td>22</td><td>− 5.6 ± 5</td></tr><tr><td><italic>Month 6</italic></td><td>22</td><td>1900 ± 370</td><td>22</td><td>− 320 ± 300<xref rid="tf0005" ref-type="table-fn">⁎</xref></td><td>22</td><td>74 ± 22</td><td>22</td><td>− 22 ± 19<xref rid="tf0005" ref-type="table-fn">⁎</xref></td><td>22</td><td>35 ± 6</td><td>22</td><td>− 4.0 ± 6</td><td>22</td><td>19 ± 6.8</td><td>22</td><td>− 5.6 ± 6<xref rid="tf0005" ref-type="table-fn">⁎</xref></td></tr><tr><td rowspan="3">LU + B420</td><td><italic>Baseline</italic></td><td>35</td><td>2090 ± 640</td><td>0</td><td>–</td><td>35</td><td>87 ± 32</td><td>0</td><td>–</td><td>35</td><td>37 ± 6</td><td>0</td><td>–</td><td>35</td><td>20 ± 6.2</td><td>0</td><td>–</td></tr><tr><td><italic>Month 2</italic></td><td>34</td><td>1990 ± 440</td><td>33</td><td>− 110 ± 530</td><td>34</td><td>79 ± 26</td><td>33</td><td>− 8.6 ± 29</td><td>34</td><td>35 ± 7</td><td>33</td><td>− 1.7 ± 7</td><td>34</td><td>16 ± 4.0</td><td>33</td><td>− 4.2 ± 6</td></tr><tr><td><italic>Month 6</italic></td><td>31</td><td>1870 ± 440</td><td>29</td><td>− 230 ± 640<xref rid="tf0005" ref-type="table-fn">⁎</xref></td><td>31</td><td>74 ± 31</td><td>29</td><td>− 10 ± 29</td><td>31</td><td>35 ± 6</td><td>29</td><td>− 1.2 ± 5</td><td>31</td><td>16 ± 5.1</td><td>29</td><td>− 3.9 ± 5</td></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>⁎</label><p id="np0005">= Significant difference from Placebo, <italic>P</italic> &lt; 0.05 (Dunnett's test, corrected for multiple comparisons). Only changes from baseline to month 6 were statistically compared between groups.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>a</label><p id="np0010">Women with energy intake &lt; 80% and men with energy intake &lt; 85% of basal metabolic rate excluded from dietary intake analyses. The energy content of the smoothie vehicle is included in the results.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>Changes in markers of endotoxemia and low-grade inflammation (Per Protocol population).</p></caption><alt-text id="al0030">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th>Placebo</th><th>LU</th><th>B420</th><th>LU + B420</th><th rowspan="2"><italic>Overall P</italic></th><th rowspan="2"><italic>Factorial P B420</italic></th><th rowspan="2"><italic>Factorial P LU</italic></th></tr><tr><th><italic>Outcome</italic></th><th></th><th><italic>Mean</italic> <italic>±</italic> <italic>SD</italic></th><th><italic>Mean</italic> <italic>±</italic> <italic>SD</italic></th><th><italic>Mean</italic> <italic>±</italic> <italic>SD</italic></th><th><italic>Mean</italic> <italic>±</italic> <italic>SD</italic></th></tr><tr><th></th><th><italic>n</italic></th><th>35–36</th><th>35–36</th><th>25</th><th>37</th><th></th><th></th><th></th></tr></thead><tbody><tr><td rowspan="3">Zonulin (ng/ml)</td><td><italic>Baseline</italic></td><td>56.5 ± 12.6</td><td>55.5 ± 9.1</td><td>58.4 ± 11.4</td><td>64.6 ± 14.2</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>59.7 ± 10.9</td><td>58.4 ± 12.0</td><td>57.1 ± 8.3</td><td>63.4 ± 13.0</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (ng/ml)</italic></td><td>+ 3.5 ± 10.0</td><td>+ 2.8 ± 8.6</td><td>− 1.2 ± 9.1</td><td>− 1.2 ± 7.0</td><td>0.10</td><td>0.063</td><td>0.84</td></tr><tr><td rowspan="3">ApoB-48 (μg/ml)</td><td><italic>Baseline</italic></td><td>11.0 ± 7.2</td><td>9.5 ± 6.9</td><td>11.1 ± 5.5</td><td>9.8 ± 4.9</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>11.0 ± 6.1</td><td>9.1 ± 5.4</td><td>12.6 ± 7.5</td><td>10.4 ± 5.7</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (</italic>μg<italic>/ml)</italic></td><td>+ 0.07 ± 5.7</td><td>− 0.44 ± 5.3</td><td>+ 1.53 ± 6.5</td><td>+ 0.56 ± 4.0</td><td>0.74<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.26<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.092<xref rid="tf9010" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="3">hsCRP (mg/l)</td><td><italic>Baseline</italic></td><td>1.73 ± 1.4</td><td>2.20 ± 2.3</td><td>2.78 ± 2.6</td><td>2.58 ± 2.6</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>2.08 ± 1.3</td><td>2.43 ± 2.30</td><td>2.22 ± 2.6</td><td>2.56 ± 2.6</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (mg/l)</italic></td><td>+ 0.35 ± 1.7</td><td>+ 0.23 ± 1.8</td><td>− 0.56 ± 2.0</td><td>− 0.02 ± 2.0</td><td>0.13<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.073<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.84<xref rid="tf9010" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="3">LPS (EU/l)</td><td><italic>Baseline</italic></td><td>65 ± 115</td><td>120 ± 206</td><td>43 ± 61</td><td>39 ± 43</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>39 ± 26</td><td>101 ± 365</td><td>51 ± 76</td><td>48 ± 42</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (</italic><italic>EU/l)</italic></td><td>− 26 ± 108</td><td>− 13 ± 341</td><td>+ 7.1 ± 39</td><td>+ 9.1 ± 40<xref rid="tf9005" ref-type="table-fn">⁎</xref></td><td>0.007<xref rid="tf9015" ref-type="table-fn">b</xref></td><td>0.094<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.22<xref rid="tf9010" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="3">sCD14 (μg/ml)</td><td><italic>Baseline</italic></td><td>1.62 ± 0.39</td><td>1.82 ± 0.43</td><td>1.80 ± 0.37</td><td>1.77 ± 0.49</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>1.80 ± 0.61</td><td>1.87 ± 0.49</td><td>1.79 ± 0.54</td><td>1.75 ± 0.43</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (</italic>μg<italic>/ml)</italic></td><td>+ 0.18 ± 0.6</td><td>+ 0.06 ± 0.5</td><td>− 0.01 ± 0.5</td><td>− 0.03 ± 0.5</td><td>0.43</td><td>0.24</td><td>0.78</td></tr><tr><td rowspan="3">IL-6 (pg/ml)</td><td><italic>Baseline</italic></td><td>10.5 ± 19</td><td>12.8 ± 20</td><td>9.0 ± 10</td><td>17.5 ± 54</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>9.2 ± 16</td><td>12.3 ± 13</td><td>11.2 ± 13</td><td>8.0 ± 10</td><td></td><td></td><td></td></tr><tr><td><italic>Δ (pg/ml)</italic></td><td>− 1.2 ± 10</td><td>− 0.54 ± 15</td><td>+ 2.2 ± 13</td><td>− 9.5 ± 47</td><td>0.72<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.42<xref rid="tf9010" ref-type="table-fn">a</xref></td><td>0.64<xref rid="tf9010" ref-type="table-fn">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="tf9005"><label>⁎</label><p id="np8005">Significant difference from Placebo, <italic>P</italic> &lt; 0.05 (Dunnett's test, corrected for multiple comparisons). Only relative changes from baseline to month 6 were statistically compared between groups.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf9010"><label>a</label><p id="np8010">Analyses on log-transformed data.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf9015"><label>b</label><p id="np8015">Non-parametric analyses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0020" position="float"><label>Table 4</label><caption><p>Changes in bacterial metabolites in feces in the Per Protocol population.</p></caption><alt-text id="al0035">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th>Placebo</th><th>LU</th><th>B420</th><th>LU + B420</th><th rowspan="2"><italic>Overall P</italic></th><th rowspan="2"><italic>Factorial P B420</italic></th><th rowspan="2"><italic>Factorial P LU</italic></th></tr><tr><th></th><th></th><th>Mean ± SD (μmol/g)</th><th><italic>Mean</italic> <italic>±</italic> <italic>SD (</italic>μmol/g)</th><th><italic>Mean</italic> <italic>±</italic> <italic>SD (</italic>μmol/g)</th><th><italic>Mean</italic> <italic>±</italic> <italic>SD (</italic>μmol/g)</th></tr><tr><th></th><th><italic>n</italic></th><th>36</th><th>35–36</th><th>24</th><th>35–37</th><th></th><th></th><th></th></tr></thead><tbody><tr><td rowspan="3">Acetic acid</td><td><italic>Baseline</italic></td><td>42.3 ± 16</td><td>43.0 ± 18</td><td>38.5 ± 21</td><td>43.7 ± 18</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>37.1 ± 14</td><td>37.6 ± 14</td><td>39.8 ± 14</td><td>41.3 ± 17</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 5.20 ± 14</td><td>− 5.76 ± 18</td><td>+ 1.34 ± 24</td><td>− 2.60 ± 18</td><td>0.34</td><td>0.13</td><td>0.99</td></tr><tr><td rowspan="3">Propionic acid</td><td><italic>Baseline</italic></td><td>11.8 ± 5.1</td><td>12.6 ± 5.7</td><td>10.7 ± 5.2</td><td>12.6 ± 5.9</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>9.9 ± 4.0</td><td>10.6 ± 5.6</td><td>11.6 ± 4.6</td><td>12.3 ± 5.9</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 1.91 ± 4.1</td><td>− 2.00 ± 6.0</td><td>+ 0.92 ± 5.8</td><td>− 0.31 ± 7.0</td><td>0.095</td><td>0.025</td><td>0.79</td></tr><tr><td rowspan="3">Butyric acid</td><td><italic>Baseline</italic></td><td>11.5 ± 6.5</td><td>10.8 ± 6.2</td><td>11.7 ± 8.6</td><td>11.7 ± 6.3</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>10.2 ± 6.0</td><td>9.2 ± 4.8</td><td>13.1 ± 9.4</td><td>10.3 ± 5.4</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 1.33 ± 6.2</td><td>− 1.58 ± 5.9</td><td>+ 1.35 ± 13</td><td>− 1.21 ± 7.2</td><td>0.45</td><td>0.0497</td><td>0.095</td></tr><tr><td rowspan="3">Valeric acid</td><td><italic>Baseline</italic></td><td>1.6 ± 0.95</td><td>1.5 ± 1.1</td><td>1.6 ± 1.1</td><td>1.9 ± 0.9</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>1.3 ± 0.81</td><td>1.4 ± 1.0</td><td>1.8 ± 1.3</td><td>1.5 ± 0.9</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 0.31 ± 0.9</td><td>− 0.08 ± 1.4</td><td>+ 0.26 ± 1.4<xref rid="tf0015" ref-type="table-fn">⁎</xref></td><td>− 0.34 ± 1.0</td><td>0.083</td><td>0.046</td><td>0.43</td></tr><tr><td rowspan="3">Lactic acid</td><td><italic>Baseline</italic></td><td>0.81 ± 0.89</td><td>0.67 ± 0.45</td><td>0.71 ± 1.04</td><td>0.65 ± 0.82</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>0.65 ± 0.69</td><td>0.88 ± 0.86</td><td>1.40 ± 2.69</td><td>0.60 ± 0.62</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 0.16 ± 0.8</td><td>+ 0.22 ± 0.8</td><td>+ 0.68 ± 2.2</td><td>+ 0.02 ± 0.7</td><td>0.14<xref rid="tf0020" ref-type="table-fn">a</xref></td><td>0.85<xref rid="tf0020" ref-type="table-fn">a</xref></td><td>0.58<xref rid="tf0020" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="3">Branched-chain fatty acids<xref rid="tf0025" ref-type="table-fn">b</xref></td><td><italic>Baseline</italic></td><td>3.86 ± 2.2</td><td>3.37 ± 2.2</td><td>3.70 ± 2.2</td><td>4.21 ± 2.0</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>2.77 ± 1.1</td><td>3.02 ± 1.5</td><td>3.76 ± 3.6</td><td>3.08 ± 1.8</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 1.09 ± 2.2</td><td>− 0.32 ± 2.7</td><td>+ 0.06 ± 3.6</td><td>− 1.20 ± 1.9</td><td>0.11</td><td>0.13</td><td>0.52</td></tr><tr><td rowspan="3">Total</td><td><italic>Baseline</italic></td><td>71.9 ± 25</td><td>71.9 ± 28</td><td>66.9 ± 33</td><td>74.7 ± 28</td><td></td><td></td><td></td></tr><tr><td><italic>Month 6</italic></td><td>61.9 ± 22</td><td>62.7 ± 23</td><td>71.5 ± 27</td><td>69.1 ± 26</td><td></td><td></td><td></td></tr><tr><td><italic>Δ</italic></td><td>− 10.0 ± 23</td><td>− 9.5 ± 28</td><td>+ 4.6 ± 41</td><td>− 5.6 ± 31</td><td>0.19</td><td>0.049</td><td>0.68</td></tr></tbody></table><table-wrap-foot><fn id="tf0015"><label>⁎</label><p id="np0015">= Significant difference from Placebo, <italic>P</italic> &lt; 0.05 (Dunnett's test, corrected for multiple comparisons). Only relative changes from baseline to month 6 were statistically compared between groups.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0020"><label>a</label><p id="np0020">Non-parametric analyses.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0025"><label>b</label><p id="np0025">Sum of isobutyric acid, isovaleric acid and 2-methyl-butyric acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article>